WO2014082548A1 - 2-芳基硒唑化合物及其药物组合物 - Google Patents
2-芳基硒唑化合物及其药物组合物 Download PDFInfo
- Publication number
- WO2014082548A1 WO2014082548A1 PCT/CN2013/087736 CN2013087736W WO2014082548A1 WO 2014082548 A1 WO2014082548 A1 WO 2014082548A1 CN 2013087736 W CN2013087736 W CN 2013087736W WO 2014082548 A1 WO2014082548 A1 WO 2014082548A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- methyl
- carboxylic acid
- cyano
- substituted
- selenoazole
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 8
- 150000001875 compounds Chemical class 0.000 claims abstract description 71
- 201000005569 Gout Diseases 0.000 claims abstract description 35
- 239000003814 drug Substances 0.000 claims abstract description 25
- 229940079593 drug Drugs 0.000 claims abstract description 22
- 150000003839 salts Chemical class 0.000 claims abstract description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 9
- 201000010099 disease Diseases 0.000 claims abstract description 8
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims abstract description 4
- 208000033679 diabetic kidney disease Diseases 0.000 claims abstract description 4
- 208000027866 inflammatory disease Diseases 0.000 claims abstract description 4
- -1 phenoxy, substituted phenoxy, phenylthio, substituted phenylthio, morpholinyl Chemical group 0.000 claims description 47
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 30
- 125000000623 heterocyclic group Chemical group 0.000 claims description 20
- 201000001431 Hyperuricemia Diseases 0.000 claims description 17
- 125000000217 alkyl group Chemical group 0.000 claims description 15
- 125000004076 pyridyl group Chemical group 0.000 claims description 15
- 229910052736 halogen Inorganic materials 0.000 claims description 12
- 150000002367 halogens Chemical class 0.000 claims description 12
- 125000001072 heteroaryl group Chemical group 0.000 claims description 12
- 125000001624 naphthyl group Chemical group 0.000 claims description 11
- 229910052739 hydrogen Inorganic materials 0.000 claims description 10
- 125000003118 aryl group Chemical group 0.000 claims description 9
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 9
- 125000001424 substituent group Chemical group 0.000 claims description 9
- 239000003064 xanthine oxidase inhibitor Substances 0.000 claims description 9
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 8
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims description 6
- 229940123769 Xanthine oxidase inhibitor Drugs 0.000 claims description 6
- 125000004494 ethyl ester group Chemical group 0.000 claims description 6
- LFAFXFBGJIKZDF-UHFFFAOYSA-N 2-(3-cyano-4-pyridin-2-ylsulfanylphenyl)-4-methyl-1,3-selenazole-5-carboxylic acid Chemical compound [se]1C(C(O)=O)=C(C)N=C1C(C=C1C#N)=CC=C1SC1=CC=CC=N1 LFAFXFBGJIKZDF-UHFFFAOYSA-N 0.000 claims description 5
- OZQRSDCVZYGMMZ-UHFFFAOYSA-N 2-[3-cyano-4-(cyclopropylmethoxy)phenyl]-4-methyl-1,3-selenazole-5-carboxylic acid Chemical compound [se]1C(C(O)=O)=C(C)N=C1C(C=C1C#N)=CC=C1OCC1CC1 OZQRSDCVZYGMMZ-UHFFFAOYSA-N 0.000 claims description 5
- 125000002252 acyl group Chemical group 0.000 claims description 5
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims description 4
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Natural products C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- 229910052805 deuterium Inorganic materials 0.000 claims description 3
- 125000001188 haloalkyl group Chemical group 0.000 claims description 3
- 230000000926 neurological effect Effects 0.000 claims description 3
- 125000005493 quinolyl group Chemical group 0.000 claims description 3
- 125000003107 substituted aryl group Chemical group 0.000 claims description 3
- XWQZGBSSSNZOIO-UHFFFAOYSA-N 2-(3-cyano-4-cyclohexylsulfanylphenyl)-4-methyl-1,3-selenazole-5-carboxylic acid Chemical compound C(#N)C=1C=C(C=CC1SC1CCCCC1)C=1[Se]C(=C(N1)C)C(=O)O XWQZGBSSSNZOIO-UHFFFAOYSA-N 0.000 claims description 2
- VWRYHVIUYDSFOD-UHFFFAOYSA-N 2-(3-cyano-4-naphthalen-1-ylphenyl)-4-methyl-1,3-selenazole-5-carboxylic acid Chemical compound [se]1C(C(O)=O)=C(C)N=C1C1=CC=C(C=2C3=CC=CC=C3C=CC=2)C(C#N)=C1 VWRYHVIUYDSFOD-UHFFFAOYSA-N 0.000 claims description 2
- JHQTYOYUPSAPLO-UHFFFAOYSA-N 2-[3-cyano-4-[4-(trifluoromethyl)phenyl]phenyl]-4-methyl-1,3-selenazole-5-carboxylic acid Chemical compound [se]1C(C(O)=O)=C(C)N=C1C(C=C1C#N)=CC=C1C1=CC=C(C(F)(F)F)C=C1 JHQTYOYUPSAPLO-UHFFFAOYSA-N 0.000 claims description 2
- XXYPCAUGDJXHHD-UHFFFAOYSA-N 4-methyl-2-[4-(2-methylpropoxy)-3-(trifluoromethyl)phenyl]-1,3-selenazole-5-carboxylic acid Chemical compound C1=C(C(F)(F)F)C(OCC(C)C)=CC=C1C1=NC(C)=C(C(O)=O)[se]1 XXYPCAUGDJXHHD-UHFFFAOYSA-N 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims description 2
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 claims description 2
- 125000000547 substituted alkyl group Chemical group 0.000 claims 10
- 125000003545 alkoxy group Chemical group 0.000 claims 6
- NIHNNTQXNPWCJQ-UHFFFAOYSA-N fluorene Chemical compound C1=CC=C2CC3=CC=CC=C3C2=C1 NIHNNTQXNPWCJQ-UHFFFAOYSA-N 0.000 claims 4
- 125000003386 piperidinyl group Chemical group 0.000 claims 4
- 125000003282 alkyl amino group Chemical group 0.000 claims 1
- 150000001350 alkyl halides Chemical class 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- 150000001735 carboxylic acids Chemical class 0.000 claims 1
- 150000002780 morpholines Chemical class 0.000 claims 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 abstract description 29
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 abstract description 26
- 229940116269 uric acid Drugs 0.000 abstract description 26
- 108010093894 Xanthine oxidase Proteins 0.000 abstract description 22
- 102100033220 Xanthine oxidase Human genes 0.000 abstract description 19
- 230000000694 effects Effects 0.000 abstract description 17
- 230000005764 inhibitory process Effects 0.000 abstract description 3
- 230000002981 neuropathic effect Effects 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 98
- 238000002474 experimental method Methods 0.000 description 65
- 230000015572 biosynthetic process Effects 0.000 description 49
- 238000003786 synthesis reaction Methods 0.000 description 49
- 235000019439 ethyl acetate Nutrition 0.000 description 40
- 238000006243 chemical reaction Methods 0.000 description 37
- 239000000203 mixture Substances 0.000 description 37
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 33
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 29
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 29
- 239000000243 solution Substances 0.000 description 25
- 230000002829 reductive effect Effects 0.000 description 23
- 239000000047 product Substances 0.000 description 21
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 17
- 239000002904 solvent Substances 0.000 description 17
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
- 125000004432 carbon atom Chemical group C* 0.000 description 14
- 238000000034 method Methods 0.000 description 14
- 238000010992 reflux Methods 0.000 description 14
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 12
- BQSJTQLCZDPROO-UHFFFAOYSA-N febuxostat Chemical compound C1=C(C#N)C(OCC(C)C)=CC=C1C1=NC(C)=C(C(O)=O)S1 BQSJTQLCZDPROO-UHFFFAOYSA-N 0.000 description 12
- 239000000741 silica gel Substances 0.000 description 12
- 229910002027 silica gel Inorganic materials 0.000 description 12
- 229960001866 silicon dioxide Drugs 0.000 description 12
- 229960005101 febuxostat Drugs 0.000 description 11
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 11
- 238000003756 stirring Methods 0.000 description 11
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 10
- 238000001816 cooling Methods 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 9
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 9
- 230000007062 hydrolysis Effects 0.000 description 9
- 238000006460 hydrolysis reaction Methods 0.000 description 9
- 229960003459 allopurinol Drugs 0.000 description 8
- 229910000027 potassium carbonate Inorganic materials 0.000 description 8
- 239000000460 chlorine Substances 0.000 description 7
- 230000029142 excretion Effects 0.000 description 7
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 6
- JXWZPOXVTBYQLO-UHFFFAOYSA-N 2-(3-cyano-4-propan-2-ylsulfanylphenyl)-4-methyl-1,3-selenazole-5-carboxylic acid Chemical compound C1=C(C#N)C(SC(C)C)=CC=C1C1=NC(C)=C(C(O)=O)[se]1 JXWZPOXVTBYQLO-UHFFFAOYSA-N 0.000 description 6
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- 229910052757 nitrogen Inorganic materials 0.000 description 6
- 239000003208 petroleum Substances 0.000 description 6
- 125000004193 piperazinyl group Chemical group 0.000 description 6
- 229940002612 prodrug Drugs 0.000 description 6
- 239000000651 prodrug Substances 0.000 description 6
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 6
- DJWSKQZSUPNTPC-UHFFFAOYSA-N 2-(3-cyano-4-phenylphenyl)-4-methyl-1,3-selenazole-5-carboxylic acid Chemical compound [se]1C(C(O)=O)=C(C)N=C1C(C=C1C#N)=CC=C1C1=CC=CC=C1 DJWSKQZSUPNTPC-UHFFFAOYSA-N 0.000 description 5
- BJFWQEZJZRRELZ-UHFFFAOYSA-N 2-[3-cyano-4-[3-(trifluoromethoxy)phenyl]phenyl]-4-methyl-1,3-selenazole-5-carboxylic acid Chemical compound C(#N)C1=C(C=CC(=C1)C=1[Se]C(=C(N1)C)C(=O)O)C1=CC(=CC=C1)OC(F)(F)F BJFWQEZJZRRELZ-UHFFFAOYSA-N 0.000 description 5
- NAZWHLLQLMAILI-UHFFFAOYSA-N 2-[3-cyano-4-[3-(trifluoromethyl)phenyl]phenyl]-4-methyl-1,3-selenazole-5-carboxylic acid Chemical compound [se]1C(C(O)=O)=C(C)N=C1C(C=C1C#N)=CC=C1C1=CC=CC(C(F)(F)F)=C1 NAZWHLLQLMAILI-UHFFFAOYSA-N 0.000 description 5
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 5
- 229940124599 anti-inflammatory drug Drugs 0.000 description 5
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical class O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 5
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 4
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 4
- VWPQHAKPTFXZFI-UHFFFAOYSA-N 2-(3-cyano-4-phenylmethoxyphenyl)-4-methyl-1,3-selenazole-5-carboxylic acid Chemical compound [se]1C(C(O)=O)=C(C)N=C1C(C=C1C#N)=CC=C1OCC1=CC=CC=C1 VWPQHAKPTFXZFI-UHFFFAOYSA-N 0.000 description 4
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 4
- RNRUTSFPBWFBJU-UHFFFAOYSA-N 2-[3-cyano-4-(4-methoxyphenyl)phenyl]-4-methyl-1,3-selenazole-5-carboxylic acid Chemical compound C1=CC(OC)=CC=C1C1=CC=C(C=2[se]C(=C(C)N=2)C(O)=O)C=C1C#N RNRUTSFPBWFBJU-UHFFFAOYSA-N 0.000 description 4
- SFJGEBNJMFJGLT-UHFFFAOYSA-N 2-[3-cyano-4-[3-(trifluoromethyl)phenyl]sulfanylphenyl]-4-methyl-1,3-selenazole-5-carboxylic acid Chemical compound [se]1C(C(O)=O)=C(C)N=C1C(C=C1C#N)=CC=C1SC1=CC=CC(C(F)(F)F)=C1 SFJGEBNJMFJGLT-UHFFFAOYSA-N 0.000 description 4
- LELWRXYBTGJGMD-UHFFFAOYSA-N 2-[4-(4-chlorophenyl)-3-cyanophenyl]-4-methyl-1,3-selenazole-5-carboxylic acid Chemical compound [se]1C(C(O)=O)=C(C)N=C1C(C=C1C#N)=CC=C1C1=CC=C(Cl)C=C1 LELWRXYBTGJGMD-UHFFFAOYSA-N 0.000 description 4
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 4
- ZSNFZUGEYMKXNZ-UHFFFAOYSA-N CC(C)CN(N)Br Chemical compound CC(C)CN(N)Br ZSNFZUGEYMKXNZ-UHFFFAOYSA-N 0.000 description 4
- XLYOFNOQVPJJNP-ZSJDYOACSA-N Heavy water Chemical compound [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 4
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 4
- WHQCHUCQKNIQEC-UHFFFAOYSA-N benzbromarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(Br)=C(O)C(Br)=C1 WHQCHUCQKNIQEC-UHFFFAOYSA-N 0.000 description 4
- 229960002529 benzbromarone Drugs 0.000 description 4
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 4
- 229910000024 caesium carbonate Inorganic materials 0.000 description 4
- 229910052801 chlorine Inorganic materials 0.000 description 4
- 125000006612 decyloxy group Chemical group 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 239000012065 filter cake Substances 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- VKYKSIONXSXAKP-UHFFFAOYSA-N hexamethylenetetramine Chemical compound C1N(C2)CN3CN1CN2C3 VKYKSIONXSXAKP-UHFFFAOYSA-N 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 239000012299 nitrogen atmosphere Substances 0.000 description 4
- 239000012074 organic phase Substances 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 239000012279 sodium borohydride Substances 0.000 description 4
- 229910000033 sodium borohydride Inorganic materials 0.000 description 4
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 4
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 4
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 3
- AIVRMJQFXVTQFW-UHFFFAOYSA-N 2-(3-cyano-4-ethoxyphenyl)-4-methyl-1,3-selenazole-5-carboxylic acid Chemical compound C1=C(C#N)C(OCC)=CC=C1C1=NC(C)=C(C(O)=O)[se]1 AIVRMJQFXVTQFW-UHFFFAOYSA-N 0.000 description 3
- ISFYDGWZVFOSLF-UHFFFAOYSA-N 2-(4-benzylsulfanyl-3-cyanophenyl)-4-methyl-1,3-selenazole-5-carboxylic acid Chemical compound [se]1C(C(O)=O)=C(C)N=C1C(C=C1C#N)=CC=C1SCC1=CC=CC=C1 ISFYDGWZVFOSLF-UHFFFAOYSA-N 0.000 description 3
- GBYPWHXCDNXFQE-UHFFFAOYSA-N 2-(4-tert-butylsulfanyl-3-cyanophenyl)-4-methyl-1,3-selenazole-5-carboxylic acid Chemical compound [se]1C(C(O)=O)=C(C)N=C1C1=CC=C(SC(C)(C)C)C(C#N)=C1 GBYPWHXCDNXFQE-UHFFFAOYSA-N 0.000 description 3
- OIWASTVUDYNHDQ-UHFFFAOYSA-N 2-(6-cyano-1-pyridin-3-ylcyclohexa-2,4-dien-1-yl)-4-methyl-1,3-selenazole-5-carboxylic acid Chemical compound C(#N)C1C=CC=CC1(C=1C=NC=CC=1)C=1[Se]C(=C(N=1)C)C(=O)O OIWASTVUDYNHDQ-UHFFFAOYSA-N 0.000 description 3
- TVBIEBOKMSVPMT-UHFFFAOYSA-N 2-(6-cyano-1-pyridin-4-ylcyclohexa-2,4-dien-1-yl)-4-methyl-1,3-selenazole-5-carboxylic acid Chemical compound CC1=C([Se]C(=N1)C2(C=CC=CC2C#N)C3=CC=NC=C3)C(=O)O TVBIEBOKMSVPMT-UHFFFAOYSA-N 0.000 description 3
- BHAKKGAABUFYHN-UHFFFAOYSA-N 2-[3-bromo-4-(2-methylpropoxy)phenyl]-4-methyl-1,3-selenazole-5-carboxylic acid Chemical compound C1=C(Br)C(OCC(C)C)=CC=C1C1=NC(C)=C(C(O)=O)[se]1 BHAKKGAABUFYHN-UHFFFAOYSA-N 0.000 description 3
- KHIAPBGXFGLAFR-UHFFFAOYSA-N 2-[3-cyano-4-(2,4-dimethoxyphenyl)phenyl]-4-methyl-1,3-selenazole-5-carboxylic acid Chemical compound COC1=CC(OC)=CC=C1C1=CC=C(C=2[se]C(=C(C)N=2)C(O)=O)C=C1C#N KHIAPBGXFGLAFR-UHFFFAOYSA-N 0.000 description 3
- QFIRBTHRBCNMLO-UHFFFAOYSA-N 2-[3-cyano-4-(2-methoxyphenyl)phenyl]-4-methyl-1,3-selenazole-5-carboxylic acid Chemical compound COC1=CC=CC=C1C1=CC=C(C=2[se]C(=C(C)N=2)C(O)=O)C=C1C#N QFIRBTHRBCNMLO-UHFFFAOYSA-N 0.000 description 3
- AAUGNNZVJNZLJZ-UHFFFAOYSA-N 2-[3-cyano-4-(3,4-difluorophenyl)phenyl]-4-methyl-1,3-selenazole-5-carboxylic acid Chemical compound [se]1C(C(O)=O)=C(C)N=C1C(C=C1C#N)=CC=C1C1=CC=C(F)C(F)=C1 AAUGNNZVJNZLJZ-UHFFFAOYSA-N 0.000 description 3
- VGMHPKSVFAHOHY-UHFFFAOYSA-N 2-[3-cyano-4-(3-methylbutoxy)phenyl]-4-methyl-1,3-selenazole-5-carboxylic acid Chemical compound C1=C(C#N)C(OCCC(C)C)=CC=C1C1=NC(C)=C(C(O)=O)[se]1 VGMHPKSVFAHOHY-UHFFFAOYSA-N 0.000 description 3
- VXUMRYMTYKDWMO-UHFFFAOYSA-N 3-bromo-4-methylbenzonitrile Chemical compound CC1=CC=C(C#N)C=C1Br VXUMRYMTYKDWMO-UHFFFAOYSA-N 0.000 description 3
- 239000000275 Adrenocorticotropic Hormone Substances 0.000 description 3
- 101100097467 Arabidopsis thaliana SYD gene Proteins 0.000 description 3
- WTMZFYPEMMFHPR-UHFFFAOYSA-N CCOC(c1c(C)nc(-c(cc2)cc(C#N)c2O)[s]1)=O Chemical compound CCOC(c1c(C)nc(-c(cc2)cc(C#N)c2O)[s]1)=O WTMZFYPEMMFHPR-UHFFFAOYSA-N 0.000 description 3
- 101800000414 Corticotropin Proteins 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 3
- VTBJTELFHCZDBM-UHFFFAOYSA-N OC1=CC=C(C=C1)C=1[Se]C(=C(N=1)C)C(=O)OCC Chemical compound OC1=CC=C(C=C1)C=1[Se]C(=C(N=1)C)C(=O)OCC VTBJTELFHCZDBM-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 102100027467 Pro-opiomelanocortin Human genes 0.000 description 3
- 206010036790 Productive cough Diseases 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 208000001647 Renal Insufficiency Diseases 0.000 description 3
- 101100495925 Schizosaccharomyces pombe (strain 972 / ATCC 24843) chr3 gene Proteins 0.000 description 3
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
- 102000005773 Xanthine dehydrogenase Human genes 0.000 description 3
- 108010091383 Xanthine dehydrogenase Proteins 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 3
- 229910052794 bromium Inorganic materials 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 3
- 229960000258 corticotropin Drugs 0.000 description 3
- RDULEYWUGKOCMR-UHFFFAOYSA-N ethyl 2-chloro-3-oxobutanoate Chemical compound CCOC(=O)C(Cl)C(C)=O RDULEYWUGKOCMR-UHFFFAOYSA-N 0.000 description 3
- 239000005457 ice water Substances 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 201000006370 kidney failure Diseases 0.000 description 3
- 125000002950 monocyclic group Chemical group 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 210000003802 sputum Anatomy 0.000 description 3
- 208000024794 sputum Diseases 0.000 description 3
- IUSARDYWEPUTPN-OZBXUNDUSA-N (2r)-n-[(2s,3r)-4-[[(4s)-6-(2,2-dimethylpropyl)spiro[3,4-dihydropyrano[2,3-b]pyridine-2,1'-cyclobutane]-4-yl]amino]-3-hydroxy-1-[3-(1,3-thiazol-2-yl)phenyl]butan-2-yl]-2-methoxypropanamide Chemical compound C([C@H](NC(=O)[C@@H](C)OC)[C@H](O)CN[C@@H]1C2=CC(CC(C)(C)C)=CN=C2OC2(CCC2)C1)C(C=1)=CC=CC=1C1=NC=CS1 IUSARDYWEPUTPN-OZBXUNDUSA-N 0.000 description 2
- STBLNCCBQMHSRC-BATDWUPUSA-N (2s)-n-[(3s,4s)-5-acetyl-7-cyano-4-methyl-1-[(2-methylnaphthalen-1-yl)methyl]-2-oxo-3,4-dihydro-1,5-benzodiazepin-3-yl]-2-(methylamino)propanamide Chemical compound O=C1[C@@H](NC(=O)[C@H](C)NC)[C@H](C)N(C(C)=O)C2=CC(C#N)=CC=C2N1CC1=C(C)C=CC2=CC=CC=C12 STBLNCCBQMHSRC-BATDWUPUSA-N 0.000 description 2
- VOAFBCREWROANP-UHFFFAOYSA-N 2-[3-bromo-4-(phenylcarbamoyl)phenyl]-4-methyl-1,3-selenazole-5-carboxylic acid Chemical compound [se]1C(C(O)=O)=C(C)N=C1C(C=C1Br)=CC=C1C(=O)NC1=CC=CC=C1 VOAFBCREWROANP-UHFFFAOYSA-N 0.000 description 2
- UVMPOFNVOXGNFV-UHFFFAOYSA-N 2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-(hydroxymethyl)-1,3-selenazole-5-carboxylic acid Chemical compound C1=C(C#N)C(OCC(C)C)=CC=C1C1=NC(CO)=C(C(O)=O)[se]1 UVMPOFNVOXGNFV-UHFFFAOYSA-N 0.000 description 2
- CNZVTBICZKIRLX-UHFFFAOYSA-N 2-[3-cyano-4-(3-fluoro-4-methoxyphenyl)phenyl]-4-methyl-1,3-selenazole-5-carboxylic acid Chemical compound C(#N)C1=C(C=CC(=C1)C=1[Se]C(=C(N1)C)C(=O)O)C1=CC(=C(C=C1)OC)F CNZVTBICZKIRLX-UHFFFAOYSA-N 0.000 description 2
- PRZPDOMUBWBXLH-UHFFFAOYSA-N 2-[4-(4-chlorophenyl)sulfanyl-3-cyanophenyl]-4-methyl-1,3-selenazole-5-carboxylic acid Chemical compound [se]1C(C(O)=O)=C(C)N=C1C(C=C1C#N)=CC=C1SC1=CC=C(Cl)C=C1 PRZPDOMUBWBXLH-UHFFFAOYSA-N 0.000 description 2
- BDFAOUQQXJIZDG-UHFFFAOYSA-N 2-methylpropane-1-thiol Chemical compound CC(C)CS BDFAOUQQXJIZDG-UHFFFAOYSA-N 0.000 description 2
- WUCILXALBXZSMZ-UHFFFAOYSA-N 3-bromo-4-(propan-2-ylsulfanylmethyl)benzonitrile Chemical compound CC(C)SCC1=CC=C(C#N)C=C1Br WUCILXALBXZSMZ-UHFFFAOYSA-N 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- VCZNNAKNUVJVGX-UHFFFAOYSA-N 4-methylbenzonitrile Chemical compound CC1=CC=C(C#N)C=C1 VCZNNAKNUVJVGX-UHFFFAOYSA-N 0.000 description 2
- XFJBGINZIMNZBW-CRAIPNDOSA-N 5-chloro-2-[4-[(1r,2s)-2-[2-(5-methylsulfonylpyridin-2-yl)oxyethyl]cyclopropyl]piperidin-1-yl]pyrimidine Chemical compound N1=CC(S(=O)(=O)C)=CC=C1OCC[C@H]1[C@@H](C2CCN(CC2)C=2N=CC(Cl)=CN=2)C1 XFJBGINZIMNZBW-CRAIPNDOSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- UJOBWOGCFQCDNV-UHFFFAOYSA-N 9H-carbazole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 2
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 2
- 239000004342 Benzoyl peroxide Substances 0.000 description 2
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- 0 CC(*)(C=CC=C1)C=C1c1nc(*)c(*)[s]1 Chemical compound CC(*)(C=CC=C1)C=C1c1nc(*)c(*)[s]1 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical group C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- UWDFWVLAHRQSKK-UHFFFAOYSA-N [3-(trifluoromethoxy)phenyl]boronic acid Chemical compound OB(O)C1=CC=CC(OC(F)(F)F)=C1 UWDFWVLAHRQSKK-UHFFFAOYSA-N 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- ORILYTVJVMAKLC-UHFFFAOYSA-N adamantane Chemical compound C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 2
- 235000019400 benzoyl peroxide Nutrition 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 229960001338 colchicine Drugs 0.000 description 2
- 229940125878 compound 36 Drugs 0.000 description 2
- 229940125807 compound 37 Drugs 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- MGNZXYYWBUKAII-UHFFFAOYSA-N cyclohexa-1,3-diene Chemical compound C1CC=CC=C1 MGNZXYYWBUKAII-UHFFFAOYSA-N 0.000 description 2
- LPIQUOYDBNQMRZ-UHFFFAOYSA-N cyclopentene Chemical compound C1CC=CC1 LPIQUOYDBNQMRZ-UHFFFAOYSA-N 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- OJCSPXHYDFONPU-UHFFFAOYSA-N etoac etoac Chemical compound CCOC(C)=O.CCOC(C)=O OJCSPXHYDFONPU-UHFFFAOYSA-N 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 239000003862 glucocorticoid Substances 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 239000004312 hexamethylene tetramine Substances 0.000 description 2
- 235000010299 hexamethylene tetramine Nutrition 0.000 description 2
- 150000002431 hydrogen Chemical class 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 239000002198 insoluble material Substances 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- AMXOYNBUYSYVKV-UHFFFAOYSA-M lithium bromide Chemical compound [Li+].[Br-] AMXOYNBUYSYVKV-UHFFFAOYSA-M 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 125000002757 morpholinyl group Chemical group 0.000 description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- HUMMCEUVDBVXTQ-UHFFFAOYSA-N naphthalen-1-ylboronic acid Chemical compound C1=CC=C2C(B(O)O)=CC=CC2=C1 HUMMCEUVDBVXTQ-UHFFFAOYSA-N 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 230000020477 pH reduction Effects 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 2
- DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 description 2
- 229960003081 probenecid Drugs 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- KJRCEJOSASVSRA-UHFFFAOYSA-N propane-2-thiol Chemical compound CC(C)S KJRCEJOSASVSRA-UHFFFAOYSA-N 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 230000009103 reabsorption Effects 0.000 description 2
- HSSLDCABUXLXKM-UHFFFAOYSA-N resorufin Chemical compound C1=CC(=O)C=C2OC3=CC(O)=CC=C3N=C21 HSSLDCABUXLXKM-UHFFFAOYSA-N 0.000 description 2
- 238000007363 ring formation reaction Methods 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 229940037128 systemic glucocorticoids Drugs 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 125000003396 thiol group Chemical group [H]S* 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 210000005239 tubule Anatomy 0.000 description 2
- 229940075420 xanthine Drugs 0.000 description 2
- SQTUYFKNCCBFRR-UHFFFAOYSA-N (2,4-dimethoxyphenyl)boronic acid Chemical compound COC1=CC=C(B(O)O)C(OC)=C1 SQTUYFKNCCBFRR-UHFFFAOYSA-N 0.000 description 1
- ROEQGIFOWRQYHD-UHFFFAOYSA-N (2-methoxyphenyl)boronic acid Chemical compound COC1=CC=CC=C1B(O)O ROEQGIFOWRQYHD-UHFFFAOYSA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- AOFUBOWZWQFQJU-SNOJBQEQSA-N (2r,3s,4s,5r)-2,5-bis(hydroxymethyl)oxolane-2,3,4-triol;(2s,3r,4s,5s,6r)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O.OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O AOFUBOWZWQFQJU-SNOJBQEQSA-N 0.000 description 1
- RULQUTYJXDLRFL-UHFFFAOYSA-N (3,4,5-trimethoxyphenyl)boronic acid Chemical compound COC1=CC(B(O)O)=CC(OC)=C1OC RULQUTYJXDLRFL-UHFFFAOYSA-N 0.000 description 1
- RMGYQBHKEWWTOY-UHFFFAOYSA-N (3,4-difluorophenyl)boronic acid Chemical compound OB(O)C1=CC=C(F)C(F)=C1 RMGYQBHKEWWTOY-UHFFFAOYSA-N 0.000 description 1
- RCVDPBFUMYUKPB-UHFFFAOYSA-N (3,4-dimethoxyphenyl)boronic acid Chemical compound COC1=CC=C(B(O)O)C=C1OC RCVDPBFUMYUKPB-UHFFFAOYSA-N 0.000 description 1
- IILGLPAJXQMKGQ-UHFFFAOYSA-N (3-fluoro-4-methoxyphenyl)boronic acid Chemical compound COC1=CC=C(B(O)O)C=C1F IILGLPAJXQMKGQ-UHFFFAOYSA-N 0.000 description 1
- NLLGFYPSWCMUIV-UHFFFAOYSA-N (3-methoxyphenyl)boronic acid Chemical compound COC1=CC=CC(B(O)O)=C1 NLLGFYPSWCMUIV-UHFFFAOYSA-N 0.000 description 1
- FNHHVPPSBFQMEL-KQHDFZBMSA-N (3S)-5-N-[(1S,5R)-3-hydroxy-6-bicyclo[3.1.0]hexanyl]-7-N,3-dimethyl-3-phenyl-2H-1-benzofuran-5,7-dicarboxamide Chemical compound CNC(=O)c1cc(cc2c1OC[C@@]2(C)c1ccccc1)C(=O)NC1[C@H]2CC(O)C[C@@H]12 FNHHVPPSBFQMEL-KQHDFZBMSA-N 0.000 description 1
- MPDDTAJMJCESGV-CTUHWIOQSA-M (3r,5r)-7-[2-(4-fluorophenyl)-5-[methyl-[(1r)-1-phenylethyl]carbamoyl]-4-propan-2-ylpyrazol-3-yl]-3,5-dihydroxyheptanoate Chemical compound C1([C@@H](C)N(C)C(=O)C2=NN(C(CC[C@@H](O)C[C@@H](O)CC([O-])=O)=C2C(C)C)C=2C=CC(F)=CC=2)=CC=CC=C1 MPDDTAJMJCESGV-CTUHWIOQSA-M 0.000 description 1
- CAYQIZIAYYNFCS-UHFFFAOYSA-N (4-chlorophenyl)boronic acid Chemical compound OB(O)C1=CC=C(Cl)C=C1 CAYQIZIAYYNFCS-UHFFFAOYSA-N 0.000 description 1
- QWMJEUJXWVZSAG-UHFFFAOYSA-N (4-ethenylphenyl)boronic acid Chemical compound OB(O)C1=CC=C(C=C)C=C1 QWMJEUJXWVZSAG-UHFFFAOYSA-N 0.000 description 1
- VOAAEKKFGLPLLU-UHFFFAOYSA-N (4-methoxyphenyl)boronic acid Chemical compound COC1=CC=C(B(O)O)C=C1 VOAAEKKFGLPLLU-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical compound C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 description 1
- PKYCWFICOKSIHZ-UHFFFAOYSA-N 1-(3,7-dihydroxyphenoxazin-10-yl)ethanone Chemical compound OC1=CC=C2N(C(=O)C)C3=CC=C(O)C=C3OC2=C1 PKYCWFICOKSIHZ-UHFFFAOYSA-N 0.000 description 1
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
- YXZFFTJAHVMMLF-UHFFFAOYSA-N 1-bromo-3-methylbutane Chemical compound CC(C)CCBr YXZFFTJAHVMMLF-UHFFFAOYSA-N 0.000 description 1
- PAMIQIKDUOTOBW-UHFFFAOYSA-N 1-methylpiperidine Chemical compound CN1CCCCC1 PAMIQIKDUOTOBW-UHFFFAOYSA-N 0.000 description 1
- WJFYLCXWEXZNHU-UHFFFAOYSA-N 2,3,3a,4-tetrahydrothieno[3,2-b]pyridine Chemical group N1C=CC=C2SCCC21 WJFYLCXWEXZNHU-UHFFFAOYSA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- ZEOSJTLLZKNHCC-UHFFFAOYSA-N 2-(3-cyano-4-propan-2-yloxyphenyl)-4-methyl-1,3-selenazole-5-carboxylic acid Chemical compound C1=C(C#N)C(OC(C)C)=CC=C1C1=NC(C)=C(C(O)=O)[se]1 ZEOSJTLLZKNHCC-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- GDGJMHSGANQKMG-UHFFFAOYSA-N 2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methyl-1,3-selenazole-5-carboxylic acid Chemical compound C1=C(C#N)C(OCC(C)C)=CC=C1C1=NC(C)=C(C(O)=O)[se]1 GDGJMHSGANQKMG-UHFFFAOYSA-N 0.000 description 1
- HLFHKDUVCDXMNB-UHFFFAOYSA-N 2-[3-cyano-4-(4-methylpiperazin-1-yl)phenyl]-4-methyl-1,3-selenazole-5-carboxylic acid Chemical compound C1CN(C)CCN1C1=CC=C(C=2[se]C(=C(C)N=2)C(O)=O)C=C1C#N HLFHKDUVCDXMNB-UHFFFAOYSA-N 0.000 description 1
- PUOKDEUGXVAWDI-UHFFFAOYSA-N 2-[3-cyano-4-[2-(trifluoromethyl)phenyl]phenyl]-4-methyl-1,3-selenazole-5-carboxylic acid Chemical compound [se]1C(C(O)=O)=C(C)N=C1C1=CC=C(C=2C(=CC=CC=2)C(F)(F)F)C(C#N)=C1 PUOKDEUGXVAWDI-UHFFFAOYSA-N 0.000 description 1
- FMKGJQHNYMWDFJ-CVEARBPZSA-N 2-[[4-(2,2-difluoropropoxy)pyrimidin-5-yl]methylamino]-4-[[(1R,4S)-4-hydroxy-3,3-dimethylcyclohexyl]amino]pyrimidine-5-carbonitrile Chemical compound FC(COC1=NC=NC=C1CNC1=NC=C(C(=N1)N[C@H]1CC([C@H](CC1)O)(C)C)C#N)(C)F FMKGJQHNYMWDFJ-CVEARBPZSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
- SCVJRXQHFJXZFZ-KVQBGUIXSA-N 2-amino-9-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-3h-purine-6-thione Chemical compound C1=2NC(N)=NC(=S)C=2N=CN1[C@H]1C[C@H](O)[C@@H](CO)O1 SCVJRXQHFJXZFZ-KVQBGUIXSA-N 0.000 description 1
- YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 1
- WYKHSBAVLOPISI-UHFFFAOYSA-N 2-phenyl-1,3-thiazole Chemical class C1=CSC(C=2C=CC=CC=2)=N1 WYKHSBAVLOPISI-UHFFFAOYSA-N 0.000 description 1
- KLLLJCACIRKBDT-UHFFFAOYSA-N 2-phenyl-1H-indole Chemical compound N1C2=CC=CC=C2C=C1C1=CC=CC=C1 KLLLJCACIRKBDT-UHFFFAOYSA-N 0.000 description 1
- 150000005360 2-phenylpyridines Chemical class 0.000 description 1
- PJRGDKFLFAYRBV-UHFFFAOYSA-N 2-phenylthiophene Chemical class C1=CSC(C=2C=CC=CC=2)=C1 PJRGDKFLFAYRBV-UHFFFAOYSA-N 0.000 description 1
- JHUUPUMBZGWODW-UHFFFAOYSA-N 3,6-dihydro-1,2-dioxine Chemical compound C1OOCC=C1 JHUUPUMBZGWODW-UHFFFAOYSA-N 0.000 description 1
- DFRAKBCRUYUFNT-UHFFFAOYSA-N 3,8-dicyclohexyl-2,4,7,9-tetrahydro-[1,3]oxazino[5,6-h][1,3]benzoxazine Chemical compound C1CCCCC1N1CC(C=CC2=C3OCN(C2)C2CCCCC2)=C3OC1 DFRAKBCRUYUFNT-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- SCURCOWZQJIUGR-UHFFFAOYSA-N 3-(trifluoromethyl)benzenethiol Chemical compound FC(F)(F)C1=CC=CC(S)=C1 SCURCOWZQJIUGR-UHFFFAOYSA-N 0.000 description 1
- OGOBINRVCUWLGN-UHFFFAOYSA-N 3-(trifluoromethyl)benzonitrile Chemical compound FC(F)(F)C1=CC=CC(C#N)=C1 OGOBINRVCUWLGN-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- BZCPLVCYTINNNM-UHFFFAOYSA-N 3-bromo-4-hydroxybenzamide Chemical compound NC(=O)C1=CC=C(O)C(Br)=C1 BZCPLVCYTINNNM-UHFFFAOYSA-N 0.000 description 1
- CRYPJUOSZDQWJZ-UHFFFAOYSA-N 3-chloro-4-hydroxybenzonitrile Chemical compound OC1=CC=C(C#N)C=C1Cl CRYPJUOSZDQWJZ-UHFFFAOYSA-N 0.000 description 1
- QTRJTMPLVIRDHO-UHFFFAOYSA-N 3-phenyl-1,2-thiazole Chemical class S1C=CC(C=2C=CC=CC=2)=N1 QTRJTMPLVIRDHO-UHFFFAOYSA-N 0.000 description 1
- QUKGHTHKDNHSOX-UHFFFAOYSA-N 4-(3-pyridin-4-yl-1h-1,2,4-triazol-5-yl)pyridine Chemical compound C1=NC=CC(C=2N=C(NN=2)C=2C=CN=CC=2)=C1 QUKGHTHKDNHSOX-UHFFFAOYSA-N 0.000 description 1
- UBVZQGOVTLIHLH-UHFFFAOYSA-N 4-[5-pyridin-4-yl-1h-[1,2,4]triazol-3-yl]-pyridine-2-carbonitrile Chemical compound C1=NC(C#N)=CC(C=2N=C(NN=2)C=2C=CN=CC=2)=C1 UBVZQGOVTLIHLH-UHFFFAOYSA-N 0.000 description 1
- VZXOZSQDJJNBRC-UHFFFAOYSA-N 4-chlorobenzenethiol Chemical compound SC1=CC=C(Cl)C=C1 VZXOZSQDJJNBRC-UHFFFAOYSA-N 0.000 description 1
- CVNOWLNNPYYEOH-UHFFFAOYSA-N 4-cyanophenol Chemical compound OC1=CC=C(C#N)C=C1 CVNOWLNNPYYEOH-UHFFFAOYSA-N 0.000 description 1
- LKXPTDCEDVRIRY-UHFFFAOYSA-N 4-hydroxy-3-(trifluoromethyl)benzamide Chemical compound NC(=O)C1=CC=C(O)C(C(F)(F)F)=C1 LKXPTDCEDVRIRY-UHFFFAOYSA-N 0.000 description 1
- ZEYHEAKUIGZSGI-UHFFFAOYSA-N 4-methoxybenzoic acid Chemical compound COC1=CC=C(C(O)=O)C=C1 ZEYHEAKUIGZSGI-UHFFFAOYSA-N 0.000 description 1
- MFFJRDFTNYKHRZ-UHFFFAOYSA-N 4-methyl-2-[3-(trifluoromethyl)phenyl]-1,3-selenazole-5-carboxylic acid Chemical compound [se]1C(C(O)=O)=C(C)N=C1C1=CC=CC(C(F)(F)F)=C1 MFFJRDFTNYKHRZ-UHFFFAOYSA-N 0.000 description 1
- JTWMOWRMSZZHDR-UHFFFAOYSA-N 7-(5-hydroxy-2-methylphenyl)-6-(2-methoxyphenyl)-4-methylpurino[7,8-a]imidazole-1,3-dione Chemical compound COC1=CC=CC=C1N(C(=CN12)C=3C(=CC=C(O)C=3)C)C2=NC2=C1C(=O)NC(=O)N2C JTWMOWRMSZZHDR-UHFFFAOYSA-N 0.000 description 1
- 208000037157 Azotemia Diseases 0.000 description 1
- PQQMCCVAOLBQLR-UHFFFAOYSA-N Br[N+]1=CC=CC=C1 Chemical compound Br[N+]1=CC=CC=C1 PQQMCCVAOLBQLR-UHFFFAOYSA-N 0.000 description 1
- JQUCWIWWWKZNCS-LESHARBVSA-N C(C1=CC=CC=C1)(=O)NC=1SC[C@H]2[C@@](N1)(CO[C@H](C2)C)C=2SC=C(N2)NC(=O)C2=NC=C(C=C2)OC(F)F Chemical compound C(C1=CC=CC=C1)(=O)NC=1SC[C@H]2[C@@](N1)(CO[C@H](C2)C)C=2SC=C(N2)NC(=O)C2=NC=C(C=C2)OC(F)F JQUCWIWWWKZNCS-LESHARBVSA-N 0.000 description 1
- PLAHZOSIYDISJR-UHFFFAOYSA-N C1(=CC=CC=C1)C1=C(C(=C(C(=C1C1=CC=CC=C1)C1=CC=CC=C1)C1=CC=CC=C1)C1=CC=CC=C1)B(O)O Chemical compound C1(=CC=CC=C1)C1=C(C(=C(C(=C1C1=CC=CC=C1)C1=CC=CC=C1)C1=CC=CC=C1)C1=CC=CC=C1)B(O)O PLAHZOSIYDISJR-UHFFFAOYSA-N 0.000 description 1
- UOZZAYDTNHHXLJ-UHFFFAOYSA-N C1(CCC1)C1=CC=CC=2C3=CC=CC=C3CC12 Chemical compound C1(CCC1)C1=CC=CC=2C3=CC=CC=C3CC12 UOZZAYDTNHHXLJ-UHFFFAOYSA-N 0.000 description 1
- PKMUHQIDVVOXHQ-HXUWFJFHSA-N C[C@H](C1=CC(C2=CC=C(CNC3CCCC3)S2)=CC=C1)NC(C1=C(C)C=CC(NC2CNC2)=C1)=O Chemical compound C[C@H](C1=CC(C2=CC=C(CNC3CCCC3)S2)=CC=C1)NC(C1=C(C)C=CC(NC2CNC2)=C1)=O PKMUHQIDVVOXHQ-HXUWFJFHSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- ZHHIMOVSUMHYJP-UHFFFAOYSA-N Cc1c(C(O)=O)[s]c(-c(cc2C#N)ccc2N(CC2)Cc3c2[s]cc3)n1 Chemical compound Cc1c(C(O)=O)[s]c(-c(cc2C#N)ccc2N(CC2)Cc3c2[s]cc3)n1 ZHHIMOVSUMHYJP-UHFFFAOYSA-N 0.000 description 1
- DRFAMFFUEYGXLV-UHFFFAOYSA-N Cc1c(C(O)=O)[s]c(-c(cc2C#N)ccc2OCc2ccccc2)n1 Chemical compound Cc1c(C(O)=O)[s]c(-c(cc2C#N)ccc2OCc2ccccc2)n1 DRFAMFFUEYGXLV-UHFFFAOYSA-N 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000252505 Characidae Species 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 101710151559 Crystal protein Proteins 0.000 description 1
- WVDYBOADDMMFIY-UHFFFAOYSA-N Cyclopentanethiol Chemical compound SC1CCCC1 WVDYBOADDMMFIY-UHFFFAOYSA-N 0.000 description 1
- 206010012434 Dermatitis allergic Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 206010070840 Gastrointestinal tract irritation Diseases 0.000 description 1
- 206010018634 Gouty Arthritis Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-N Metaphosphoric acid Chemical compound OP(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-N 0.000 description 1
- MGQYEILVGLSMRU-UHFFFAOYSA-N N#Cc1cc(Br)c(CBr)cc1 Chemical compound N#Cc1cc(Br)c(CBr)cc1 MGQYEILVGLSMRU-UHFFFAOYSA-N 0.000 description 1
- PVCJKHHOXFKFRP-UHFFFAOYSA-N N-acetylethanolamine Chemical compound CC(=O)NCCO PVCJKHHOXFKFRP-UHFFFAOYSA-N 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 241000219061 Rheum Species 0.000 description 1
- 102100030935 Solute carrier family 2, facilitated glucose transporter member 9 Human genes 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 description 1
- SPXSEZMVRJLHQG-XMMPIXPASA-N [(2R)-1-[[4-[(3-phenylmethoxyphenoxy)methyl]phenyl]methyl]pyrrolidin-2-yl]methanol Chemical compound C(C1=CC=CC=C1)OC=1C=C(OCC2=CC=C(CN3[C@H](CCC3)CO)C=C2)C=CC=1 SPXSEZMVRJLHQG-XMMPIXPASA-N 0.000 description 1
- AIJCNTOYZPKURP-UHFFFAOYSA-N [2-(trifluoromethoxy)phenyl]boronic acid Chemical compound OB(O)C1=CC=CC=C1OC(F)(F)F AIJCNTOYZPKURP-UHFFFAOYSA-N 0.000 description 1
- HUOFUOCSQCYFPW-UHFFFAOYSA-N [4-(trifluoromethoxy)phenyl]boronic acid Chemical compound OB(O)C1=CC=C(OC(F)(F)F)C=C1 HUOFUOCSQCYFPW-UHFFFAOYSA-N 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- UGAPHEBNTGUMBB-UHFFFAOYSA-N acetic acid;ethyl acetate Chemical compound CC(O)=O.CCOC(C)=O UGAPHEBNTGUMBB-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229910001413 alkali metal ion Inorganic materials 0.000 description 1
- 229910001420 alkaline earth metal ion Inorganic materials 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 125000001769 aryl amino group Chemical group 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- UHOVQNZJYSORNB-UHFFFAOYSA-N benzene Substances C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 1
- AWHNUHMUCGRKRA-UHFFFAOYSA-N benzylsulfonylmethylbenzene Chemical compound C=1C=CC=CC=1CS(=O)(=O)CC1=CC=CC=C1 AWHNUHMUCGRKRA-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940127204 compound 29 Drugs 0.000 description 1
- 229940127271 compound 49 Drugs 0.000 description 1
- 229940127113 compound 57 Drugs 0.000 description 1
- 229940126179 compound 72 Drugs 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 235000020247 cow milk Nutrition 0.000 description 1
- CHVJITGCYZJHLR-UHFFFAOYSA-N cyclohepta-1,3,5-triene Chemical compound C1C=CC=CC=C1 CHVJITGCYZJHLR-UHFFFAOYSA-N 0.000 description 1
- GUDMZGLFZNLYEY-UHFFFAOYSA-N cyclopropylmethanol Chemical compound OCC1CC1 GUDMZGLFZNLYEY-UHFFFAOYSA-N 0.000 description 1
- DUSHUSLJJMDGTE-ZJPMUUANSA-N cyproterone Chemical compound C1=C(Cl)C2=CC(=O)[C@@H]3C[C@@H]3[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 DUSHUSLJJMDGTE-ZJPMUUANSA-N 0.000 description 1
- 229960003843 cyproterone Drugs 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 125000004212 difluorophenyl group Chemical group 0.000 description 1
- 125000005805 dimethoxy phenyl group Chemical group 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000042 effect on ischemia Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- BJXYHBKEQFQVES-NWDGAFQWSA-N enpatoran Chemical compound N[C@H]1CN(C[C@H](C1)C(F)(F)F)C1=C2C=CC=NC2=C(C=C1)C#N BJXYHBKEQFQVES-NWDGAFQWSA-N 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- VEUUMBGHMNQHGO-UHFFFAOYSA-N ethyl chloroacetate Chemical compound CCOC(=O)CCl VEUUMBGHMNQHGO-UHFFFAOYSA-N 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 239000001307 helium Substances 0.000 description 1
- 229910052734 helium Inorganic materials 0.000 description 1
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 231100000304 hepatotoxicity Toxicity 0.000 description 1
- 150000002391 heterocyclic compounds Chemical class 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- QMXCTKPNQFJZGK-UHFFFAOYSA-N hydron;4,5,6,7-tetrahydrothieno[3,2-c]pyridine;chloride Chemical compound Cl.C1NCCC2=C1C=CS2 QMXCTKPNQFJZGK-UHFFFAOYSA-N 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 230000007056 liver toxicity Effects 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- ILUJQPXNXACGAN-UHFFFAOYSA-N ortho-methoxybenzoic acid Natural products COC1=CC=CC=C1C(O)=O ILUJQPXNXACGAN-UHFFFAOYSA-N 0.000 description 1
- RYDICHIKLKVOEJ-UHFFFAOYSA-N oxadiazepine Chemical compound O1C=CC=CN=N1 RYDICHIKLKVOEJ-UHFFFAOYSA-N 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 125000003544 oxime group Chemical group 0.000 description 1
- RGSFGYAAUTVSQA-UHFFFAOYSA-N pentamethylene Natural products C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 1
- JQQSUOJIMKJQHS-UHFFFAOYSA-N pentaphenyl group Chemical group C1=CC=CC2=CC3=CC=C4C=C5C=CC=CC5=CC4=C3C=C12 JQQSUOJIMKJQHS-UHFFFAOYSA-N 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 238000009522 phase III clinical trial Methods 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- 150000008048 phenylpyrazoles Chemical class 0.000 description 1
- 125000003356 phenylsulfanyl group Chemical group [*]SC1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- NWELCUKYUCBVKK-UHFFFAOYSA-N pyridin-2-ylhydrazine Chemical compound NNC1=CC=CC=N1 NWELCUKYUCBVKK-UHFFFAOYSA-N 0.000 description 1
- QLULGIRFKAWHOJ-UHFFFAOYSA-N pyridin-4-ylboronic acid Chemical compound OB(O)C1=CC=NC=C1 QLULGIRFKAWHOJ-UHFFFAOYSA-N 0.000 description 1
- FGVVTMRZYROCTH-UHFFFAOYSA-N pyridine-2-thiol N-oxide Chemical compound [O-][N+]1=CC=CC=C1S FGVVTMRZYROCTH-UHFFFAOYSA-N 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 229960002026 pyrithione Drugs 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000001739 rebound effect Effects 0.000 description 1
- 125000006413 ring segment Chemical group 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical compound [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- WMXCDAVJEZZYLT-UHFFFAOYSA-N tert-butylthiol Chemical compound CC(C)(C)S WMXCDAVJEZZYLT-UHFFFAOYSA-N 0.000 description 1
- 150000003536 tetrazoles Chemical class 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 229950004176 topiroxostat Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 1
- 125000001680 trimethoxyphenyl group Chemical group 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 238000007039 two-step reaction Methods 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 108010078530 urate transporter Proteins 0.000 description 1
- 208000009852 uremia Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D293/00—Heterocyclic compounds containing rings having nitrogen and selenium or nitrogen and tellurium, with or without oxygen or sulfur atoms, as the ring hetero atoms
- C07D293/02—Heterocyclic compounds containing rings having nitrogen and selenium or nitrogen and tellurium, with or without oxygen or sulfur atoms, as the ring hetero atoms not condensed with other rings
- C07D293/04—Five-membered rings
- C07D293/06—Selenazoles; Hydrogenated selenazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D421/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having selenium, tellurium, or halogen atoms as ring hetero atoms
- C07D421/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having selenium, tellurium, or halogen atoms as ring hetero atoms containing two hetero rings
- C07D421/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having selenium, tellurium, or halogen atoms as ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D421/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having selenium, tellurium, or halogen atoms as ring hetero atoms
- C07D421/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having selenium, tellurium, or halogen atoms as ring hetero atoms containing two hetero rings
- C07D421/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having selenium, tellurium, or halogen atoms as ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Definitions
- the invention relates to a class of 2-arylselenoazole compounds and their use, in particular to the field of medicinal chemistry.
- the invention further relates to a process for the preparation of such compounds, to pharmaceutical compositions containing these compounds and to their use in medical use, in particular as a xanthine oxidase inhibitor for the treatment of gout and hyperuricemia.
- Gout is a disease caused by excessive accumulation of uric acid and deposition of sodium urate in the body due to disturbances in sputum metabolism in the body. Gout is the second largest metabolic disease after diabetes, which has been listed by the United Nations as one of the top 20 chronic diseases of the 21st century. Epidemiological studies at home and abroad have shown that the incidence of hyperuricemia and gouty disease is increasing with the improvement of human living standards and the prolongation of human life expectancy. It has been reported that in the decade of 1990-1999, the incidence of gout arthritis in the United States increased from 0.29% to 0.52% (Arthur L. Weaver. Epidemiology of gout [J] .
- Uric acid is the metabolic end product of guanidine in nucleic acids in the body, including nucleic acids in food. Its content is related to the catabolism rate of nucleic acids in the body and the excretory function of the kidney.
- uric acid When the production of uric acid is increased or the excretion is reduced, uric acid can accumulate and hyperuricemia occurs. It is generally believed that the serum uric acid content at 37 ° C is > 420 mol / L (70 mg / L) for men and > 360 mol / L for women (60 When it is mg/L), it is hyperuricemia.
- Gout can also cause many complications. According to statistics, 90% of patients with gout will cause impotence, nephritis, stones, etc., and 50% of patients with complications such as chronic kidney disease and heart disease are prone to severe deformation of the joint and 30% of patients are disabled. Death caused by diseases such as uremia and renal failure (Grobner W, Walter-Sack I. Treatment of hyperuricemia and gout [J] . Med Monatsschr Pharm. 2005, 28 (5): 159-164). Gout is also associated with hypertension, metabolic syndrome, hyperlipidemia, diabetes, insulin resistance, and many other conditions (Terkeltaub RA. Cl inical practice. Gout [J] . N Engl J Med. 2003, 349 : 1647-1655 (Schlesinger N, Schumacher HR Jr. Gout: can management be improved? [J] . Curr Opin Rheumatol. 2001, 13 : 240-244)
- the main drugs for treating gout are anti-inflammatory drugs, uric acid excretion drugs, and uric acid-producing drugs.
- Some anti-inflammatory drugs such as colchicine, non-inflammatory anti-inflammatory drugs (NSAIDS), adrenocorticotropic hormone (ACTH), glucocorticoids, etc. are mainly used to treat acute gouty arthritis, which can relieve temporary pain in patients.
- colchicine is often accompanied by common adverse reactions such as diarrhea, vomiting, and abdominal pain.
- Non-organic anti-inflammatory drugs can relieve pain in a short period of time, but most non-organic anti-inflammatory drugs are accompanied by severe gastrointestinal tract. reaction.
- Adrenocorticotropic hormone and glucocorticoids can inhibit non-infectious inflammation, reduce congestion and edema, inhibit inflammatory cell migration, reduce autoimmune levels, and are used to treat patients with severe acute gout with systemic symptoms, but these drugs have Very strong rebound effect.
- uric acid Reducing uric acid levels in the body is mainly solved by promoting uric acid excretion and reducing uric acid production.
- the main excretion drugs for promoting uric acid in the body are: probenecid, sulfinoxazolone, benzbromarone and the like.
- This kind of medicine can inhibit the reabsorption of uric acid by renal tubules and act on the urate transporter of renal proximal convoluted tubules, thereby inhibiting the reabsorption of uric acid and increasing its excretion, thereby reducing the concentration of uric acid in the body.
- Another class of drugs for treating gout is to inhibit uric acid production.
- these drugs mainly inhibit the conversion of sputum to uric acid by inhibiting the activity of Xanthine oxidase (X0) required during sputum metabolism, thereby fundamentally reducing the production of uric acid and thus treating gout. effect.
- Allopurinol which was marketed in the 1960s, is an analogue of hypoxanthine and a competitive inhibitor of xanthine oxidase.
- Febuxostat is a new generation of xanthine oxidase inhibitors that are clinically used to prevent and treat hyperuricemia and gout caused by it. Teijin was applied for listing in Japan in early 2004, the European Union approved its listing in May 2008, and the US FDA approved its listing in February 2009. Febuxostat inhibits the oxidized and reduced states of xanthine oxidase. In contrast, allopurinol has a weak ability to inhibit oxidation state xanthine oxidase.
- Febuxostat is mainly metabolized by the liver, and the metabolism and excretion of allopurinol mainly through the kidneys can better avoid the adverse reactions of allopurinol due to kidney metabolism and excretion (Takano Y, Hase-Aoki K, Horiuchi H et al. Selectivity of febuxostat, a novel non-pur ine inhibitor of xanthine oxidase/ xanthine dehydrogenase [J] . Life Sci. 2005, 76 : 1835-1847 ) (Becker MA, Schumacher HR Jr, Wortman RL. Febuxostat compared with Allopurinol in patients with hyper-uricemia and gout [J] .
- Phase III clinical trial report The plasma uric acid level was below 60 mg/L at the end of treatment in the treatment group compared with the control group.
- Patients with allopurinol sensitivity are well accommodating to febuxostat. 8 ( ⁇ 120 mg/day of febuxostat is more effective than 300 mg/day of allopurinol to lower blood urate levels (Pohar S, Murphy G. Febuxostat for prevention of gout attacks [J] Issues Emerg Health Technol. 2006, 87 : 1-4).
- xanthine oxidase inhibitors targeting xanthine oxidase are almost all heterocyclic compounds, and most of them are nitrogen heterocyclic aromatic compounds, for example, phenylpyrazole derivatives have been reported (W09818765, JP10310578).
- Another object of the present invention is to provide a above-mentioned 2-arylselenoazole compound for preparing a xanthine oxidase inhibitor, or for preparing or preventing high uric acid, gout, diabetic nephropathy, inflammatory disease, neurological system disease And other uses for drugs.
- the object of the invention can be achieved by the following measures:
- X is selected from d fluorenyl or d substituted fluorenyl
- Y is selected from -C00R a or -CONHIT
- R 1 is selected from halogen, -CN, d- 2 fluorenyl, d- 2 substituted fluorenyl, d- 3 decyloxy or -3 substituted decyloxy;
- R 2 is selected from the group consisting of H, D, halogen, d- 2 fluorenyl, d- 2 substituted fluorenyl, d- 3 decyloxy or - 3 substituted decyloxy;
- R 3 is selected from -(CH 2 ) compassion- 0- R b , -(CH 2 ) n - S- R b , - C (0) R b , - NR d , - S (0) CHR3 ⁇ 4 d , - S (0) 2 CHR d , - (CH 2 ) felicitC (0) NR d , an aryl group, a substituted aryl group, a heterocyclic group, a substituted heterocyclic group, a heteroaryl group or a substituted heteroaryl group;
- n 0- 2 ;
- R a is selected from H, d- 6 fluorenyl or d- 6 substituted fluorenyl;
- R b is selected from the group consisting of H, d- 8 fluorenyl, d- 8 substituted fluorenyl, aryl, substituted aryl, heterocyclic, substituted heterocyclic, heteroaryl or substituted heteroaryl;
- R° and R d are each independently selected from H, d- 8 fluorenyl or d- 8 substituted fluorenyl; or RPR d cyclized to form a cyclodecyl, a substituted cyclodecyl, a heterocyclic or a substituted heterocyclic;
- R d substituents are selected from D, - 0H, - CN, - NH 2, acyl, amido, halo, d embankment group, d embankment haloalkyl group, d deuterated alkyl with, d embankment or a group - One or more of 2 amino groups.
- the 2-arylselenoazole compound of the present invention may further be a compound having a structure represented by the formula (II) or a pharmaceutically acceptable salt thereof.
- X is d fluorenyl or d halogen or hydroxy substituted fluorenyl
- X is -CH 3 , -CH 2 CH 3 , -CH 2 0H or -CF 3 .
- X is -CH 3 .
- Y is -C00R a , which is ⁇ d- 3 fluorenyl or d- 3 substituted fluorenyl.
- Y is -C00H.
- R 1 is selected from the group consisting of halogen, -CN, d-decyl, d-haloindolyl, d-decyloxy or d-halodecyloxy.
- R 1 is selected from the group consisting of halogen, -CN, -CH 3 , -C CH 3 , -CHF 2 , -CF 3 , - 0CHF 2 or - 0CF 3 .
- R 1 is selected from the group consisting of Cl, Br, -CN, -CF 3 .
- R 2 is selected from H or D.
- the compound of the present invention may be a compound of formula (III) or a pharmaceutically acceptable compound thereof
- R 3 is selected from the group consisting of - 0R b , - SR b , - C(0)R b , - NR d , - S(0)CHR d , - S(0) 2 CHR3 ⁇ 4 d , -C (0)NR3 ⁇ 4 d , phenyl, substituted phenyl, pyridyl, substituted pyridyl, naphthyl, substituted naphthyl, phenoxy, substituted phenoxy, phenylthio, substituted phenylthio, morpholinyl, substituted Morpholinyl, N-ethylmorpholinyl, substituted N-ethylmorpholinyl, piperazinyl, substituted piperazinyl, tetrahydrothienopyridinyl, phenylsulfonyl or substituted benzsulfonyl;
- R 3 is selected from - 0R b , - SR b , - C(0)R b , - NR d , - S(0) 2 CHR3 ⁇ 4 d , - C(0)NR3 ⁇ 4 d , phenyl, substituted phenyl , pyridyl, substituted pyridyl, naphthyl, substituted naphthyl, quinolyl, substituted quinolyl, phenylthio, substituted phenylthio, phenoxy, substituted phenoxy, pyridylthio, morpholinyl, Piperazinyl, substituted piperazinyl or tetrahydrothienopyridinyl; in a preferred embodiment, ⁇ is ( ⁇ 8 fluorenyl, d- 8 substituted indenyl, phenyl or substituted phenyl; R or R d each Independently selected from H, d- 8 fluorenyl or
- the substituent is selected from the group consisting of D, -0H, -NH 2 , -CN, acyl, halogen, d- 4 fluorenyl, C-halogenated fluorenyl, d- 4 fluorenyl or d - one or more of 2 methoxy groups.
- the substituent is selected from the group consisting of D, -OH, -NH 2 , -CN, -NHCH 3 , - F, - Cl, - Br, - CH 3 , - CH 2 CH 3 , - CHDCH 2 D, - One or more of CF 3 , - 0CH 3 or - 0CH 2 CH 3 .
- R 3 is selected from the group consisting of - 0C CH 3 , - 0CH(CH 3 ) 2 , - 0CH 2 CH(CH 3 ) 2 , - 0CH 2 CH 2 CH(CH 3 ) 2 , - 0C C 6 H dilemma, - 0C C 3 H 5 , - SCH(CH 3 ) 2 , - SCH 2 CH(CH 3 ) 2 , - S(0) 2 CH(CH 3 ) 2 , - CH 2 SCH(CH 3 ) 2 , -N(CH 3 ) 2 , phenyl, monomethoxyphenyl, dimethoxyphenyl, trimethoxyphenyl, methoxyfluorophenyl, trifluoromethoxyphenyl, chlorine Phenyl, difluorophenyl, pentaphenyl, methylpiperazinylphenyl, benzoyl, benzylidene, benzyloxy, nap
- the 2-arylselenoazole compound of the present invention which may be further selected from the following compounds or pharmaceutically acceptable salts thereof:
- the compound of the present invention 2-(3-cyano-4-isopropylthiophenyl)-4-methyl-selenoazole-5-carboxylic acid-(2-N-acetyl)ethyl ester is 2-(3- Possible prodrugs (Prodrug) of cyano-4-isopropylthiophenyl)-4-methyl-selenoazole-5-carboxylic acid.
- the compound of the present invention can be produced by the above-described or similar preparation methods, and the corresponding starting materials can be selected depending on the substituents and the position of the substituent.
- the preparation by a special method will be specifically described in the examples.
- Haldrogen means ⁇ (1H), which is the main stable isotope of hydrogen.
- ⁇ refers to a stable morphological isotope of hydrogen, also known as heavy hydrogen, whose element is D.
- mercapto a saturated aliphatic hydrocarbon group of 1 to 20 carbon atoms, including straight-chain and branched-chain groups (the numerical ranges mentioned in this application, such as “1-20”, mean the group, In this case, it is a sulfhydryl group and may have one carbon atom, two carbon atoms, three carbon atoms, etc., up to and including 20 carbon atoms.
- a fluorenyl group having 1 to 4 carbon atoms is referred to as a lower fluorenyl group. When the lower fluorenyl group has no substituent, it is referred to as an unsubstituted lower fluorenyl group.
- the fluorenyl group is a medium sized fluorenyl group having 1 to 10 carbon atoms, such as methyl, ethyl, propyl, 2-propyl, n-butyl, isobutyl, tert-butyl, pentyl Base.
- the fluorenyl group is a lower fluorenyl group having 1 to 4 carbon atoms, such as a methyl group, an ethyl group, a propyl group, a 2-propyl group, a n-butyl group, an isobutyl group or a t-butyl group.
- the thiol group can be substituted or unsubstituted.
- Cycloalkyl in the present invention means a monocyclic or fused ring which is all carbon (the “fused” ring means that each ring in the system shares an adjacent pair of carbon atoms with other rings in the system). a group, wherein one or more of the rings does not have a fully connected ⁇ -electron system, which typically has from 3 to 10 carbon atoms, and embodiments of the cycloalkyl group (not limited to) are cyproterone, cyclobutyl fluorene, cyclopentamidine , cyclopentene, cyclohexanthene, adamantane, cyclohexadiene, cycloheptadene and cycloheptatriene.
- the cycloalkyl group can be substituted and unsubstituted.
- heterocyclic group in the present invention includes “heterocyclic fluorenyl group” and “heteroaryl group”.
- heterocyclic fluorenyl means a monocyclic or fused saturated ring containing at least one heteroatom ("fused" ring means that each ring in the system shares an adjacent pair of carbon atoms with other rings in the system)
- fused ring means that each ring in the system shares an adjacent pair of carbon atoms with other rings in the system
- a group in which one or more of the rings does not have a fully attached pi-electron system, which typically has from 3 to 10 carbon atoms.
- heteroaryl group in the present invention means a monocyclic or fused ring group of 5 to 12 ring atoms, and contains one, two, three or four ring hetero atoms selected from ⁇ 0 or S, and the remaining rings.
- the atom is C and additionally has a fully conjugated ⁇ -electron system.
- unsubstituted heteroaryl bases are pyrrole, furan, thiophene, imidazole, oxazole, thiazole, pyrazole, pyrimidine, quinoline, isoquinoline, indole, tetrazole, triazine and carbazole.
- Heteroaryl groups can be substituted or unsubstituted.
- aryl group in the present invention means an all-carbon monocyclic or fused polycyclic group of 6 to 12 carbon atoms, and has a fully conjugated ⁇ -electron system.
- Non-limiting examples of aryl groups are phenyl, naphthyl and anthracenyl.
- the aryl group can be substituted or unsubstituted.
- Hydrolysis means a -0 oxime group.
- Network means a -0-(unsubstituted indenyl) group and a -0-(unsubstituted cycloalkyl) group, which further represents -0- (unsubstituted indenyl).
- Representative examples include, but are not limited to, methoxy, ethoxy, propoxy, butoxy, cyclopropoxy, cyclobutoxy, cyclopentyloxy, cyclohexyloxy, and the like.
- Phenyl means a group attached to any other group on the benzene ring (I).
- Phenylthio represents an -S-phenyl group.
- Phenoxy means a -0-phenyl group.
- Halogen means fluorine, chlorine, bromine or iodine, preferably fluorine, chlorine or bromine.
- Cyano means a -CN group.
- Niro means a -N0 2 group.
- Acyl means a -C(0)Q group, wherein Q may be hydrogen (ie formyl), or may be fluorenyl, decylamino, aryl, arylamino, etc., such as acetyl, propionyl, benzoyl Acyl, benzoyl and the like.
- Amino means a -NH 2 group.
- Deuterated thiol means a group in which one or more hydrogens are replaced by deuterium.
- Nephthyl means a group in which a naphthalene ring is bonded to another group at any point.
- pyridyl means pyridyl A group in which any of the 2-6 positions is attached to another group.
- Pyridinylthio means a -S-pyridyl group
- Morpholinyl represents a morpholino any one site (including N-) group attached to the other groups on ring t () in bits 2-6
- Porture means a group attached to any of the sites (including N-) on the piperazine ring ( ).
- benzylsulfone On ((3 ⁇ 4-) groups attached to other groups.
- Tetrahydrothienopyridyl means a tetrahydrothienopyridine ring ( Any of the above-mentioned sites that can be attached to other groups (including N-) to which other groups are attached.
- the "C and "d in the "C cyclodecyl-substituted d-methoxy" group in the present invention only defines the number of carbon atoms in the immediately adjacent group, and is not the number of carbon atoms of the entire group.
- “Pharmaceutically acceptable salt” is a salt of a compound comprising formula (I) or formula ( ⁇ ) with an organic or inorganic acid, meaning those salts which retain the biological effectiveness and properties of the parent compound.
- Such salts include:
- an organic base such as ethanolamine, diethanolamine, or the like. Ethanolamine, tromethamine, N-methylglucamine, and the like.
- “Pharmaceutical composition” refers to a mixture of one or more of the compounds described herein or their pharmaceutically acceptable salts and prodrugs with other chemical ingredients, such as pharmaceutically acceptable carriers and excipients. .
- the purpose of the pharmaceutical composition is to facilitate administration of the compound to the organism.
- Prodrug refers to a compound that has a pharmacological effect after transformation in vivo.
- the prodrug itself has no biological activity or activity and is metabolized into an active substance. The purpose of this process is to increase the bioavailability of the drug, enhance the targeting, and reduce the toxicity and side effects of the drug.
- the present invention includes a pharmaceutical composition comprising the compound of any one of the present invention or a pharmaceutically acceptable salt thereof as an active ingredient.
- the compound of the present invention or a pharmaceutically acceptable salt thereof can be used for the preparation of a xanthine oxidase inhibitor drug.
- the compound of the present invention or a pharmaceutically acceptable salt thereof can be used for the preparation of a medicament for preventing or treating hyperuricemia, gout, diabetic nephropathy, inflammatory disease, neurological system disease.
- Step A Anhydrous ethanol (540 mL) was added dropwise to a mixture of selenium powder (50.0 g, 0.633 mol) and sodium borohydride (26.4 g, 0.698 mol) in an ice water bath under a nitrogen atmosphere. After warming up to room temperature, stirring was continued for 1 hour. Then add a solution of p-hydroxyphenyl cyanide (18.84 g, 0.158 mol) in pyridine (126 mL), warm to reflux, and slowly add 2M hydrochloric acid solution (320 mL), and add the time for not less than 4 hours. Stir at reflux overnight. TLC analysis indicated the end of the reaction.
- Step B Compound 1 (25.0 g, 0.125 mol) and ethyl 2-chloroacetoacetate (24.7 g, 0.150 mol) were added to anhydrous ethanol (500 mL), and stirred under reflux for 3 hours. TLC analysis indicated the end of the reaction. The reaction solution was cooled to room temperature, suction filtered under reduced pressure, and the filter cake was collected and dried to give ethyl 2-(4-hydroxyphenyl)-4-methyl-selenazole-5-carboxylate (2) (32.7 g). Rate: 84.3%.
- Step C Compound 2 (17.6 g, 56.7 mmol) and hexamethylenetetramine (HMTA) (9.8 g, 69.9 mmol) were added to trifluoroacetic acid (85 mL), and the mixture was warmed to 85 ° C. Hours, TLC analysis indicated the end of the reaction. Most of the solvent was evaporated under reduced pressure, and then water (300 mL) was added dropwise, and the mixture was stirred for 60 minutes, then filtered, and then filtered and evaporated to ethyl acetate (200 mL). The solvent was evaporated under reduced pressure, and the obtained product was purified mjjjjjjjjjjj 4-methyl- Selenium-ethyl 5-formate (3) (8.7 g), yield: 45.3%.
- HMTA hexamethylenetetramine
- Step D Compound 3 (8.7 g, 25.7 mmol), hydroxylamine hydrochloride (2.6 g, 37.4 mmol) and sodium formate (2.5 g, 36.7 mmol) were added to formic acid (90 mL). Analysis indicated that the reaction was over. The reaction solution was cooled to room temperature, and water (270 mL) was added dropwise, and a large amount of solid was precipitated, then further cooled to 0-5 ° C, stirred for 30 minutes, filtered, and the filter cake was washed with a large amount of water and dried under vacuum to give a pale yellow solid.
- Step E Compound 4 (70 mg, 0.209 mmol) was dissolved in DMF (5 mL). Potassium iodide (7 mg, 0.042 mmol), anhydrous potassium carbonate (34.7 mg, 0.251 mmol) and bromoethyl bromide (32 mg) , 0.293 mmol), the resulting mixture was stirred at 70 ° C overnight.
- Step F Compound 5 obtained in the previous step was dissolved in THF (4 mL) and methanol (11 mL), and 2M sodium hydroxide solution (3 mL) was added, and the mixture was warmed to 55 ° C and stirred for 0.5 hour. After the completion of the reaction, about half of the solvent was evaporated under reduced pressure, water (20 mL) was added, and the mixture was adjusted to pH 6 with dilute hydrochloric acid, filtered and dried to give 2-(3-cyano-4-ethoxyphenyl)- 4-Methyl-selenoazole-5-carboxylic acid (6).
- Step A Compound 4 (7.0 g, 20.9 mmol) was suspended in anhydrous dichloromethane (100 mL). DMP (262 mg, 2.14 mmol) and pyridine (7.0 mL) were added. The mixture was cooled, trifluoromethanesulfonic acid anhydride (10.8 mL) was added dropwise, and stirring was continued for 1 hour in an ice salt bath, and TLC analysis indicated that the reaction was completed. Dichloromethane was evaporated under reduced pressure.
- Step B Toluene (10 mL) and four were added to a mixture of compound 13 (110 mg, 0.235 mmol), phenylboronic acid (52.7 mg, 0.422 mmol) and anhydrous potassium carbonate (53 mg, 0.384 mmol) (Triphenylphosphine)palladium (20 mg, 0.017 mmol), the resulting mixture was warmed to 110 ° C under nitrogen and stirred overnight.
- Step B (2) The ester obtained in the step B (1) is hydrolyzed according to the experimental procedure F in Example 1, and acidified to give 2-(2-cyano-biphenyl-4-yl)-4-methyl- Selenazole-5-carboxylic acid (14).
- Step A Toluene (10 mL) was added to a mixture of compound 13 (110 mg, 0.235 mmol), 4-vinylbenzeneboronic acid (39 mg, 0.264 mmol) and anhydrous potassium carbonate (53 mg, 0.384 mmol). Tetrakis(triphenylphosphine)palladium (20 mg, 0.017 mmol), the reaction was heated to 110 ° C under nitrogen and stirred overnight.
- Step B Compound 29 was dissolved in THF (10 mL) and heavy water (1 mL), 5% palladium carbon (20 mg) was added, and the mixture was subjected to a hydration reaction under atmospheric pressure for 24 hours. Filtration through celite, the filtrate was evaporated under reduced pressure. Hydrolyzed according to the experimental procedure F in Example 1, and acidified to give 2-[2-cyano-4'-(1,2-decanoethyl)-biphenyl-4-yl]-4-methyl- Selenazole-5-carboxylic acid (30).
- Step A NBS (160 mg, 0.898 mmol) was added portionwise to a mixture of compound 4 (250 mg, 0.745 mmol), methanol (8 mL) and triethylamine (1 mL) in an ice-water bath. The reaction was stirred for 1 hour. The solvent was evaporated under reduced pressure, and the obtained product was dissolved in ethyl acetate (25 mL), filtered to remove insoluble materials, washed with water, adjusted to pH 2-3, filtered, and the collected solid was directly used for the next reaction.
- Step B The product obtained in the previous step was dissolved in DMF (3 mL), anhydrous potassium carbonate (240 mg, 1.739 mmol) and benzyl bromide (159 mg, 0.930 mmol) were added, and the mixture was warmed to 60 ° C. After 20 minutes, DMF (5 mL) was added and the reaction was kept for 2 hours. Cool to room temperature, dilute with water (45 mL), filter, and dry the filter cake for the next reaction.
- Step C The product obtained in the previous step was dissolved in DMF (10 mL) and heavy water (1 mL), and 5% palladium carbon (30 mg) was added, and the resulting mixture was subjected to a hydrazine reaction under normal pressure for 24 hours in a helium gas. The celite pad was filtered, and the solvent was evaporated under reduced pressure to give ethyl 2-(3-cyano-4-hydroxy-5-deutero-phenyl)-4-methyl-selenoazole-5-carboxylate (33) (102 mg), total yield of three-step reaction: 40.6%.
- Step D Dissolve compound 33 (102 mg, 0.302 mmol) in dichloromethane (10 mL), add DMP (4 mg, 0.033 mmol) and pyridine (0.1 mL), then add trifluorohexane in ice water bath Formazanic anhydride (257 mg, 0.910 mmol), the reaction was stirred for 1 hour under ice water. The majority of the chloroform was distilled off under reduced pressure, then water (10 mL) was evaporated and evaporated with ethyl acetate (10 mL EtOAc).
- Step E Toluene (10 mL) and tetrakis (triphenylbenzene) were added to a mixture of compound 34 (70 mg, 0.149 mmol), phenylboronic acid (33.5 mg, 0.275 mmol) and anhydrous potassium carbonate (33.7 mg, 0.244 mmol). Palladium (20 mg, 0.017 mmol), the reaction was warmed to 110 ° C under nitrogen and stirred overnight.
- the reaction solution is cooled to room temperature, via diatom
- Step A To a three-necked flask A was added 1,4-dioxane (4 mL), isopropyl mercaptan (27 mg, 0.355 mmol) and diisopropylethylamine (61 mg 0.472 mmol) under nitrogen. The mixture was stirred at room temperature for 40 minutes.
- Step B Compound 36 was hydrolyzed according to the procedure of Example 1 in Example 1, and acidified to give 2-(3-cyano-4-isopropylthiophenyl)-4-methyl-selenoazole-5-carboxylic acid. (37).
- Step A At (TlO'C, dry ethanol (36 mL) was slowly added dropwise to a mixture of selenium powder (3.3 g, 41.8 mmol) and sodium borohydride (1.73 g, 45.8 mmol). Stirring was continued for 30 minutes at room temperature, then a solution of pyridine (8.3 mL) containing 3-chloro-4-hydroxybenzonitrile (1.6 g, 10.4 mmol) was added. The reaction mixture was warmed to reflux and then 2 M hydrochloric acid solution (21 mL) After the addition was completed, the mixture was refluxed for 1 hour, and TLC analysis indicated that the reaction was completed.
- Step B Compound 49 (2.4 g, 10.2 mmol) was dissolved in EtOAc (EtOAc)EtOAc. TLC analysis indicated the end of the reaction. The reaction solution was cooled to room temperature, suction filtered and dried to give ethyl 2-(3-chloro-4-hydroxyphenyl)-4-methyl-selenoazole-5-carboxylate (50) (3.1 g) Rate: 88.
- the compound 3-trifluoromethyl-4-hydroxybenzamide was prepared according to the experimental procedure A of Example 32, followed by the ring closure reaction according to the experimental procedure B in Example 32, followed by the example in Example 32.
- Experimental step C was reacted with bromoisobutyl hydrazine, finally hydrolyzed according to the experimental procedure F in Example 1, and acidified to give 2-(3-trifluoromethyl-4-isobutoxyphenyl)-4-methyl Base-selenazole-5-carboxylic acid (55).
- Step A Concentrated sulfuric acid (20 mL) was added dropwise to water (20 mL) to form a sulfuric acid solution, then 4-methylbenzonitrile (5.86 g, 50.0 mmol) and NBS (8.9 g) were added at (T5 °C). , 50.0 mmol), the mixture was stirred at room temperature overnight, filtered, and filtered, ethyl acetate (150 mL) was dissolved with water (30 mL ⁇ 2), aqueous sodium bicarbonate (30 mL), saturated brine (20) The extract was washed with anhydrous sodium sulfate. The solvent was evaporated under reduced pressure to give 3-bromo-4-methylbenzonitrile (57) (6.78 g), yield: 69.2%.
- Step B Compound 57 (804 mg, 4.04 mmol) was dissolved in carbon tetrachloride (8 mL), then NBS (730 mg, 4.10 mmol) and benzoyl peroxide (7 mg, 0.0289 mmol). Heat under nitrogen to reflux and stir overnight. After cooling to room temperature, the insoluble material was removed by filtration, and the solvent was evaporated under reduced pressure, and then ethyl acetate (30 mL) was dissolved and washed with water (10 mL) and brine (10 mL). The solvent was evaporated under reduced pressure, and then purified to silicagel eluted eluted eluted eluted eluted ), Yield: 52.5%.
- Step D Slowly add anhydrous ethanol (10 mL) to selenium powder (340 mg, 4.306 mmol) and sodium borohydride (178 mg, 4.709 mmol) under TlO'C, and warm to room temperature after the addition. Stirring was continued for 30 minutes. Then a solution of compound 59 (270 mg, 1.0 mmol) in pyridine (1.5 mL) was added, and the mixture was warmed to reflux, then 2M hydrochloric acid solution (10 mL) was slowly added dropwise. After the addition, reflux stirring was continued for 1 hour, TLC Analysis shows the end of the reaction. Cool to room temperature, add water (30 mL) was diluted with ethyl acetate (15 mL ⁇ 3). The combined organic phases were washed with 2M hydrochloric acid (15 mL) and brine (15 mL). - Isopropylthiomethylselenobenzamide (60), this product was used directly in the next reaction.
- Step F Compound 61 (115 mg, 0.249 mmol) was dissolved in N-methylpyrrolidone (6 mL), then cuprous cyanide (40 mg, 0.446 mmol) was added, then warmed to reflux and stirred for 6 hours under nitrogen. . The solvent was evaporated under reduced pressure, and then purified using silica gel eluting eluting eluting eluting eluting eluting eluting eluting Base) 4-methyl-selenoazole-5-carboxylic acid ethyl ester.
- Step A Compound 58 (2.6 g, 9.46 mmol) was dissolved in 1,4-dioxane (20 mL) and water (20 mL). Stir overnight. After cooling to room temperature, water (40 mL) was added, and ethyl acetate (30 mL EtOAc) was evaporated. 63) (1.8 g), yield: 89.7%.
- Step B Slowly add anhydrous ethanol (27 mL) to a mixture of selenium powder (2.7 g, 34.2 mmol) and sodium borohydride (1.57 g, 41.5 mmol) at (TlO'C). Stirring was continued for 30 minutes at room temperature, then a solution of 3-bromo-4-isopropylthiomethylbenzonitrile 63 (1.8 g, 8.49 mmol) in pyridine (7.2 mL) was added and warmed to reflux, then 2 M hydrochloric acid was slowly added dropwise. The solution (18 mL) was stirred and refluxed for 1 hour after the addition. TLC analysis indicated the end of the reaction.
- Step C Compound 64 (293 mg, 1.0 mmol) was dissolved in ethyl acetate (10 mL), ethyl 2-chloroacetate (197 mg, 1.20 mmol). TLC analysis indicated the end of the reaction. After cooling to room temperature, an appropriate amount of water was added dropwise, and filtered to give ethyl 2-(3-bromo-4-hydroxymethylphenyl)-4-methyl-selenoazole-5-carboxylate (65) (340 mg). Yield: 84.3%.
- Step D Compound 65 (200 mg, 0.496 mmol) was dissolved in acetone (5 mL), then potassium permanganate (158 mg, 1.0 mmol) was added and stirred at room temperature for 2 hours and then quenched with aqueous sodium hydrogen sulfite After the addition, the appropriate amount of water was added, and the insoluble matter was removed by filtration. The filtrate was extracted with ethyl acetate (20 mL ⁇ 2), and the aqueous phase was adjusted to pH 3-4 with 2 M hydrochloric acid, and filtered to give 2-(3-bromo-4-carboxybenzene). Ethyl 4-methyl-selenazole-5-carboxylate (66) (168 mg), Yield: 81.2%.
- Step E Compound 66 (147 mg, 0.352 mmol) was dissolved in dichloromethane (10 mL), then thionyl chloride (168 mg, 1.41 mmol), then warmed to reflux and stirred for 3 hr. Solvent. Then, dichloromethane (10 mL) was added, and triethylamine (107 mg, 1.059 mmol) and aniline (33 mg, 0.354 mmol) were added, and the ice bath was removed, and the mixture was stirred at room temperature for 1 hour. The reaction solution was washed with an appropriate amount of water and dried over anhydrous sodium sulfate.
- step B in Example 8 in which the cesium carbonate was used instead of potassium carbonate in the reaction (1).
- Compound 13 was reacted with 3-trifluoromethoxybenzeneboronic acid according to Experimental Procedure B (1) in Example 8, and cesium carbonate was used in place of potassium carbonate. Then, it was hydrolyzed according to the experimental procedure F in Example 1, and acidified to obtain 2-(2-cyano-3'-trifluoromethylbiphenyl-4-yl)-4-methyl-selenoazole-5-carboxylic acid. (69).
- Step B Compound 71 (1.1 g, 2.811 mmol) was dissolved in carbon tetrachloride (25 mL), then NBS (0.55 g, 3.090 mmol) and benzoyl peroxide (0.40 g, 1.65 mmol). The mixture was heated to reflux under a nitrogen atmosphere and then stirred overnight. The solvent was evaporated under reduced pressure, and then purified, mjjjjjjjjj Ethyl 4-bromomethyl-selenazole-5-carboxylate (72) (0.91 g), Yield: 68.8%.
- Step C Compound 72 (0.90 g, 1.914 mmol) was dissolved in 1,4-dioxane (15 mL) and water (15 mL), then calcium carbonate (0.80 g, 8.0 mmol). , continue stirring under reflux overnight. After cooling to room temperature, water (30 mL) was added, and ethyl acetate (30 mL EtOAc) was evaporated. Purified to give 2-(3-cyano-4-isobutoxybenzene Ethyl 4-hydroxymethyl-selenoazole-5-carboxylate (73) (0.20 g), Yield: 25.7%.
- Step D Compound 73 is hydrolyzed according to the procedure of Step F in Example 1, and acidified to give 2-(3-cyano-4-isobutoxyphenyl)-4-hydroxymethyl-selenoazole-5-carboxylic acid ( 74).
- the compound 3-bromo-4-hydroxybenzamide was prepared according to the experimental procedure A in Example 36, followed by the ring closure reaction according to the experimental procedure B in Example 32, followed by the experimental procedure C in Example 32. Reaction with bromoisobutyl hydrazine, finally hydrolysis according to the experimental procedure F in Example 1, and acidification to give 2-(3-bromo-4-isobutoxyphenyl)-4-methyl-selenoazole-5 - Formic acid (78).
- Example 47 Synthesis of (3-cyano-4-cyclohexylthiophenyl)-4-methyl-selenoazole-5-carboxylic acid (83) The compound was reacted with cyclopentanethiol according to the experimental procedure A in Example 25, followed by hydrolysis according to the experimental procedure F in Example 1, and acidified to give 2-(3-cyano-4-cyclohexylthiophenyl). 4-methyl-selenoazole-5-carboxylic acid (83).
- Step A Anhydrous ethanol (30 mL) was added dropwise to a mixture of selenium powder (1.84 g 23.3 mmol) and sodium borohydride (0.97 g 25.6 mmol) in an ice water bath under a nitrogen atmosphere. Stirring was continued for 30 minutes. Then, a solution of 3-trifluoromethylbenzonitrile (1.0 g, 5.84 mmol) in pyridine (6 mL) was added, and the mixture was warmed to reflux, and then 2 M hydrochloric acid solution (4 mL) was slowly added dropwise. . TLC analysis indicated the end of the reaction. The ethanol was evaporated under reduced pressure. EtOAc (EtOAc) (EtOAc (EtOAc) The solvent was evaporated under reduced pressure to give 3-trifluoromethyl succinamide (84) (1.6 g).
- Step B Compound 84 (1.0 g NMT 3.65 ol) and ethyl 2-chloroacetoacetate (653 mg, 3.97 mmol) were added to anhydrous ethanol (10 mL), and the mixture was stirred at reflux for 2 hours. TLC analysis indicated the end of the reaction. The reaction solution was cooled to room temperature, suction filtered under reduced pressure, and the filtered cake was dried and evaporated to give ethyl 2-(3-trifluoromethylphenyl)-4-methyl-selenoazole-5-carboxylate (85) (930 mg) ), total yield of two-step reaction: 70.3%
- Step C Compound 85 was hydrolyzed according to the procedure of Step 1 in Example 1 and acidified to give 2-(3-trifluoromethylphenyl)-4-methyl-selenazole-5-carboxylic acid (86).
- xanthine Oxidase Xanthine Oxidase
- HRP Horseradish Peroxidase
- horseradish peroxidase catalyzes the reaction of hydrogen peroxide with 10-acetyl-3, 7-dihydroxyphenoxazine (Ampl iflu Red) to produce a strong fluorescent compound, Resorufin, and the fluorescence intensity of resorufin is determined by fluorescence microplate reader. It is directly proportional to xanthine oxidase activity.
- test compound and the control compound febuxostat were dissolved in DMS0 (product of Sinopharm Chemical Reagent Co., Ltd.).
- DMS0 product of Sinopharm Chemical Reagent Co., Ltd.
- the test compound was serially diluted with a DMSO solution in a 96-well polypropylene reaction plate (Greeer Bio One product) to obtain a 200-fold concentration solution. Further, it was diluted in ultrapure water to obtain a serial dilution solution of 3 times concentration.
- Reaction solution A 6 mU/mL xanthine oxidase (from cow's milk, Sigma product) was prepared in a 0.1 M Tris-HCl (pH 7.5) buffer solution.
- Reaction solution B Horseradish peroxidase (product of Shanghai Yuanye Biotechnology Co., Ltd.), 0. 15 U/mL was prepared in a buffer solution of 0.1 M Tri s-HCl (pH 7.5). A mixture of mM Ampl iflu Red (Sigma product) and 0.3 mM hypoxanthine (Sigma product). The solution is protected from light at 4 ° C and is now ready for use. 9 reaction solution A was mixed with 9 ⁇ L of the test compound in a 3-fold serial dilution solution in a 96-well test plate (Greiner Bio One product), placed on a plate shaker, and mixed at 30 rpm for 30 minutes at 100 rpm. .
- Table 1 Compound xanthine oxidase inhibitor activity IG
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/648,664 US9802907B2 (en) | 2012-11-30 | 2013-11-24 | 2-aryl selenazole compound and pharmaceutical composition thereof |
EP13858539.3A EP2927219B1 (en) | 2012-11-30 | 2013-11-24 | 2-aryl selenazole compound and pharmaceutical composition thereof |
JP2015544335A JP6143877B2 (ja) | 2012-11-30 | 2013-11-24 | 2−アリールセレナゾール化合物及びその薬剤組成物 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210504310.8 | 2012-11-30 | ||
CN201210504310.8A CN103848798B (zh) | 2012-11-30 | 2012-11-30 | 2-芳基硒唑化合物及其药物组合物 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2014082548A1 true WO2014082548A1 (zh) | 2014-06-05 |
Family
ID=50827179
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2013/087736 WO2014082548A1 (zh) | 2012-11-30 | 2013-11-24 | 2-芳基硒唑化合物及其药物组合物 |
Country Status (5)
Country | Link |
---|---|
US (1) | US9802907B2 (zh) |
EP (1) | EP2927219B1 (zh) |
JP (1) | JP6143877B2 (zh) |
CN (1) | CN103848798B (zh) |
WO (1) | WO2014082548A1 (zh) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103936693B (zh) * | 2013-01-22 | 2016-06-15 | 沈阳药科大学 | 2-(3-氰基-4-取代苯基)-4-甲基-1,3-硒唑-5-甲酸及其酯类化合物和制备方法 |
CN108358866B (zh) * | 2017-01-12 | 2021-03-23 | 江西同和药业股份有限公司 | 一种非布司他中间体的制备方法及其在制备非布司他中的应用 |
CN111662239B (zh) * | 2019-03-06 | 2023-07-28 | 中国医学科学院药物研究所 | 1,2,4-三唑类化合物及其制法和药物用途 |
CN113354616B (zh) * | 2020-03-05 | 2024-03-26 | 中国医学科学院药物研究所 | 二芳基-1,2,4-三唑类化合物及其制法和药物用途 |
CN116390922A (zh) * | 2020-10-21 | 2023-07-04 | 南京明德新药研发有限公司 | 硒杂环类化合物及其应用 |
WO2023202706A1 (zh) * | 2022-04-21 | 2023-10-26 | 南京明德新药研发有限公司 | 硒杂环类化合物的盐型和晶型及其应用 |
Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06211815A (ja) | 1993-01-19 | 1994-08-02 | Teijin Ltd | イソキサゾールおよびイソチアゾール誘導体 |
WO1996031211A1 (fr) | 1995-04-07 | 1996-10-10 | Teijin Limited | Agent protecteur pour organe ou tissu |
US5614520A (en) * | 1990-11-30 | 1997-03-25 | Teijin Limited | 2-arylthiazole derivatives and pharmaceutical composition thereof |
WO1998018765A1 (fr) | 1996-10-25 | 1998-05-07 | Yoshitomi Pharmaceutical Industries, Ltd. | Composes de 1-phenylpyrazole et leur application pharmaceutique |
JPH10310578A (ja) | 1996-11-13 | 1998-11-24 | Yoshitomi Pharmaceut Ind Ltd | 3−フェニルピラゾール化合物 |
JP2002105067A (ja) | 2000-09-28 | 2002-04-10 | Teijin Ltd | 2−フェニルチアゾール誘導体、およびそれを有効成分とする医薬組成物 |
WO2005121153A1 (ja) | 2004-06-14 | 2005-12-22 | Nippon Chemiphar Co., Ltd. | 縮合ピリミジン誘導体、及びキサンチンオキシダーゼ阻害剤 |
WO2006022375A1 (ja) | 2004-08-27 | 2006-03-02 | Astellas Pharma Inc. | 2-フェニルチオフェン誘導体 |
WO2006022374A1 (ja) | 2004-08-27 | 2006-03-02 | Astellas Pharma Inc. | 2-フェニルピリジン誘導体 |
WO2007043457A1 (ja) | 2005-10-07 | 2007-04-19 | Astellas Pharma Inc. | トリアリールカルボン酸誘導体 |
CN102781924A (zh) * | 2010-02-25 | 2012-11-14 | 首尔大学校产学协力财团 | 用作过氧化物酶体增殖剂激活受体的配体的硒唑衍生物、其制备方法及其化合物的用途 |
CN103130744A (zh) * | 2012-08-28 | 2013-06-05 | 沈阳药科大学 | 一种硒唑甲酸类化合物及其制备方法和用途 |
-
2012
- 2012-11-30 CN CN201210504310.8A patent/CN103848798B/zh active Active
-
2013
- 2013-11-24 EP EP13858539.3A patent/EP2927219B1/en not_active Not-in-force
- 2013-11-24 WO PCT/CN2013/087736 patent/WO2014082548A1/zh active Application Filing
- 2013-11-24 US US14/648,664 patent/US9802907B2/en active Active
- 2013-11-24 JP JP2015544335A patent/JP6143877B2/ja not_active Expired - Fee Related
Patent Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5614520A (en) * | 1990-11-30 | 1997-03-25 | Teijin Limited | 2-arylthiazole derivatives and pharmaceutical composition thereof |
JPH06211815A (ja) | 1993-01-19 | 1994-08-02 | Teijin Ltd | イソキサゾールおよびイソチアゾール誘導体 |
WO1996031211A1 (fr) | 1995-04-07 | 1996-10-10 | Teijin Limited | Agent protecteur pour organe ou tissu |
WO1998018765A1 (fr) | 1996-10-25 | 1998-05-07 | Yoshitomi Pharmaceutical Industries, Ltd. | Composes de 1-phenylpyrazole et leur application pharmaceutique |
JPH10310578A (ja) | 1996-11-13 | 1998-11-24 | Yoshitomi Pharmaceut Ind Ltd | 3−フェニルピラゾール化合物 |
JP2002105067A (ja) | 2000-09-28 | 2002-04-10 | Teijin Ltd | 2−フェニルチアゾール誘導体、およびそれを有効成分とする医薬組成物 |
WO2005121153A1 (ja) | 2004-06-14 | 2005-12-22 | Nippon Chemiphar Co., Ltd. | 縮合ピリミジン誘導体、及びキサンチンオキシダーゼ阻害剤 |
WO2006022375A1 (ja) | 2004-08-27 | 2006-03-02 | Astellas Pharma Inc. | 2-フェニルチオフェン誘導体 |
WO2006022374A1 (ja) | 2004-08-27 | 2006-03-02 | Astellas Pharma Inc. | 2-フェニルピリジン誘導体 |
WO2007043457A1 (ja) | 2005-10-07 | 2007-04-19 | Astellas Pharma Inc. | トリアリールカルボン酸誘導体 |
CN102781924A (zh) * | 2010-02-25 | 2012-11-14 | 首尔大学校产学协力财团 | 用作过氧化物酶体增殖剂激活受体的配体的硒唑衍生物、其制备方法及其化合物的用途 |
CN103130744A (zh) * | 2012-08-28 | 2013-06-05 | 沈阳药科大学 | 一种硒唑甲酸类化合物及其制备方法和用途 |
Non-Patent Citations (12)
Title |
---|
ARTHUR L. WEAVER: "Epidemiology of gout [J", CLEVELAND CLINIC JOURNAL OF MEDICINE, vol. 75, no. 5, 2008, pages S9 - S 12 |
BECKER MA; SCHUMACHER HR JR; WORTMAN RL: "Febuxostat compared with allopurinol in patients with hyper-uricemia and gout[J", N ENGL J MED., vol. 353, 2005, pages 2450 - 2461 |
GROBNER W; WALTER-SACK I: "Treatment of hyperuricemia and gout[J", MED MONATSSCHR PHARM, vol. 28, no. 5, 2005, pages 159 - 164 |
HAIRONG NAN; QING QIAO; YANHU DONG ET AL.: "The prevalence of hyperuricemia in apopulation of the coastal city of Qingdao", CHINA[J]. THE JOURNAL OF RHEUMATOLOGY, vol. 33, no. 7, 2006, pages 1346 - 1350 |
JANSEN TL; REINDERS MK; VAN ROON EN ET AL.: "Benzbromarone with drawn from the European market: another case of ''absence of evidence is evidence of absence''?[J", CLIN EXP RHEUMATOL, vol. 22, no. 5, 2004, pages 651 |
L. ANNEMANS; E SPAEPEN; M GASKIN ET AL.: "Gout in the UK and Germany: prevalence, comorbidities, and management in general practice 2000-2005[J].", ANN RHEUM DIS, vol. 67, 2008, pages 960 - 966 |
NAKAZAWA T; MIYATA K; OMURA K ET AL.: "Metabolic profile of FYX-051 (4-(5-pyridin-4-yl-1H-[1,2,4] triazol-3-yl) pyridine -2-carbonitrile) in the rat, dog, monkey, and human: identification of N-glucuronides and N-glucosides[J", DRUG METAB DISPOS, vol. 34, no. 11, 2006, pages 1880 - 1886 |
POHAR S; MURPHY G: "Febuxostat for prevention of gout attacks [J", ISSUES EMERG HEALTH TECHNOL., vol. 87, 2006, pages 1 - 4 |
RAQUEL VILLEGAS; YONG BING XIANG; QIU YIN CAI ET AL.: "Prevalence and Determinants of Hyperuricemia in Middle-Aged, Urban Chinese Men[J", METABOLIC SYNDROME AND RELATED DISORDERS, vol. 8, no. 3, 2010, pages 263 - 270 |
SCHLESINGER N; SCHUMACHER HR JR: "Gout: can management be improved?[J", CURR OPIN RHEUMATOL., vol. 13, 2001, pages 240 - 244 |
TAKANO Y; HASE-AOKI K; HORIUCHI H ET AL.: "Selectivity of febuxostat, a novel non-purine inhibitor of xanthine oxidase/xanthine dehydrogenase[J", LIFE SCI., vol. 76, 2005, pages 1835 - 1847, XP004732269, DOI: doi:10.1016/j.lfs.2004.10.031 |
TERKELTAUB RA: "Clinical practice. Gout[J", N ENGL J MED., vol. 349, 2003, pages 1647 - 1655 |
Also Published As
Publication number | Publication date |
---|---|
EP2927219A4 (en) | 2016-07-06 |
CN103848798A (zh) | 2014-06-11 |
JP2016500115A (ja) | 2016-01-07 |
US9802907B2 (en) | 2017-10-31 |
EP2927219B1 (en) | 2018-05-30 |
CN103848798B (zh) | 2016-01-06 |
US20150291543A1 (en) | 2015-10-15 |
JP6143877B2 (ja) | 2017-06-07 |
EP2927219A1 (en) | 2015-10-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2014082548A1 (zh) | 2-芳基硒唑化合物及其药物组合物 | |
RU2515968C2 (ru) | 5-членное гетероциклическое соединение и его применение для лекарственных целей | |
AU2019373702A1 (en) | Diphenyl-like compound, intermediate thereof, preparation method therefor, pharmaceutical composition thereof and uses thereof | |
JP3895404B2 (ja) | カルコン誘導体及びこれを含有する医薬 | |
WO2008054454A2 (en) | Nitrogen-containing heterocycle derivatives, pharmaceutical compositions, and methods of use thereof as antiviral agents | |
WO2005115374A1 (en) | Crth2 receptor ligands for therapeutic use | |
JP2022530405A (ja) | N-メチル-2-ピリドンを含む化合物、および薬学的に許容される塩 | |
WO2017041732A1 (zh) | 一类用于治疗或预防高尿酸血症或痛风的化合物 | |
CA2578168A1 (en) | 2-phenylpyridine derivative | |
TW201819364A (zh) | Urat1抑制劑及其應用 | |
TWI844849B (zh) | 一類黃嘌呤氧化酶抑制劑 | |
WO2020043173A1 (zh) | 作为受体相互作用蛋白1(rip1)激酶抑制剂的杂环化合物 | |
CN113906020A (zh) | 用于治疗皮肤病的缓激肽(bk)b2受体拮抗剂的(r)-3-(氯-5-氟-2-((4-(1h-吡唑-1-基)-2-甲基喹啉-8-基氧基)甲基)苯基)吗啉衍生物及相关的化合物 | |
FR2941948A1 (fr) | Derives d'azaindoles en tant qu'inhibiteur des proteines kinases abl et src | |
JP2024521946A (ja) | Tyk2阻害剤としてのヘテロアリール化合物、その組成物及び用途 | |
JP2013533258A (ja) | 細胞増殖を阻害するための化合物 | |
CN112243437B (zh) | 含丙烯酰基的核转运调节剂及其用途 | |
CN106045898B (zh) | 一种吲哚类化合物及其制备方法和用途 | |
WO2018214961A1 (zh) | 促尿酸排泄的urat1抑制剂 | |
JP6612882B2 (ja) | プテリジンジオンモノカルボン酸トランスポータ阻害薬 | |
TW201843135A (zh) | 胺基-芳基-苯甲醯胺化合物及其使用方法 | |
JP7450951B2 (ja) | 新型fxr小分子作動剤の製造およびその使用 | |
TW202003467A (zh) | Urat-1抑制劑的新型鹽形式 | |
WO2018210207A1 (zh) | 用于治疗痛风或高尿酸血症的磺酰胺类化合物及其制备方法 | |
JPH08231514A (ja) | フェニルベンズイミダゾール誘導体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13858539 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2015544335 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14648664 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2013858539 Country of ref document: EP |